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ABSTRACT 
 
While many ligands are known to interact with the opioid receptor system, most can be 
traced back to the common morphine scaffold. In several cases ligands have been developed that 
are selective for either the mu, kappa, or delta opioid receptors. Selective kappa opioid receptor 
agonists and antagonists have shown potential to be used to decrease cocaine self-administration 
and be utilized in the treatment of relapse. The emergence of salvinorin A as a novel scaffold, 
that selectively interacts with the kappa opioid receptor, retains therapeutic potential with a 
reduced side effect profile to the current treatments. Traditional mu opioid ligands, such as 
morphine, have life threatening side effects such as respiratory depression and constipation 
among other drawbacks like tolerance and dependence.  
To fully investigate the potential of salvinorin A as a viable alternative for therapeutic 
treatment it must be isolated in high purity for pharmacological evaluation. In efforts to isolate 
high purity salvinorin A, a reactive handle was generated that was shown to undergo 
cycloaddition to the furan ring of salvinorin A. This handle was developed using the reactivity 
limitations that were also investigated for the Diels-Alder cycloaddition of electron deficient 
alkenes and alkynes with the salvinorin A furan ring.  
In order to understand the unique mode of interaction salvinorin A imparts on the opioid 
receptor system, investigations into the pharmacological profile of salvinorin A were explored. 
Analytical methods were developed for the identification and quantification of salvinorin A from 
non-human primate cerebrospinal fluid and human plasma. This method was then exploited to 
develop a time-course graph for the measurement of in vivo concentrations of salvinorin A in 
various biological fluids which could be correlated to subjective and biological observations.  
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CHAPTER I 
 
Natural Product History 
Natural products, single chemical entities produced by a living organism, have been around 
longer than mankind itself. Having the advantage of time, natural products have had hundreds of 
millions of years to evolve before intelligent life began recognizing their use as medicinal 
agents.
1
 Since early prehistoric times natural products and their extracts have been used in 
medicine and often as the only known means of treatment.
2-4
 After thousands of years of using 
natural products, their utility and traditional uses have been passed along first by word of mouth 
between communal members and later becoming systematically written into books for the whole 
world to share, making once locally known remedies readily available. For instance, it is now 
common knowledge that extracts or teas made from chamomile can help relax and remove 
tension, ginger can be used to ease nausea, peppermint will soothe indigestion, and that bacopa 
will reduce stress and symptoms of depression. The use of natural products for medical purposes 
in fact includes a wide variety of sources including ginger, lemon balm, catnip, rosemary, aloe, 
green tea, and sage.
5, 6
  
As civilization advanced, we looked first to natural products as treatments, then began 
eventually isolating their individual active components for more effective treatments.
7
 From 
these isolated compounds, a large percentage of commonly used ancient treatments were found 
to contain basic nitrogen atoms, becoming known as plant alkaloids.
3
 These alkaloids consisted 
of common compounds such as atropine, nicotine, cocaine, ephedrine, tubocurarine, quinine, and 
2 
 
morphine (Figure 1). In today’s scientific community many of these compounds have been 
investigated not only for their therapeutic drug potential, but also to investigate the physiological 
mechanisms by which they operate. Even with today’s scientific advances, over 75% of the 
world population utilizes natural or traditional treatments for medicinal therapeutics, with a 
strong popularity remaining even in industrialized areas of the world.
8
  
 
With their widespread use in traditional medicines and remedies, natural products have vastly 
influenced the modern pharmaceutical industry, helping shape it into what we know today. The 
influence that natural products have on the modern pharmaceutical industry has resulted in over 
half of all modern pharmaceuticals being derived from or based on a natural product.
9, 10
 From 
1981 to 2010 approximately 70% of the top selling drugs were natural products or inspired by 
natural products, having a place in nearly every therapeutic area.
9-11
 While nature is undisputedly 
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a great source in the search for biologically active agents, the complexity of natural products can 
often lead to many problems with their development into usable agents. These very hurdles that 
encompass natural products on a whole are often times the same reasons which attract scientists 
to them. Organic chemists have struggled in synthesizing even milligrams of a complex natural 
product which nature makes in large quantities with ease, while pharmacologists discover unique 
pathways after a natural product illicits a biological response.
12-14
 This study of natural products 
has lead to developments in the field of organic chemistry by pushing past the limits of known 
chemical syntheses as well as in pharmacology by providing biochemical probes for the 
elucidation of pathways of disease.
9, 15
 The overall advancement of science through the study of 
natural products has helped mold modern medicine by providing an assorted set of novel 
molecules with complex diversity.
7, 14, 16
  
Limitations of Natural Products 
Historically natural products have been very successful as sources for leads and drug 
candidates in pharmaceutical industry.
7, 15
 Even though a large percentage of new drugs today are 
either derived from or are natural products, many of the natural product-based research programs 
within large pharmaceutical industry are being closed.
16
 Traditionally, the sets of compounds 
tested against drug targets were largely composed of natural products or compounds derived 
from natural products. However, these libraries were composed mainly of compounds closely 
related to one another, such as thousands of steroids or -lactams. As the pharmaceutical 
industry began expanding its search for lead compounds and drug targets, it also began looking 
for increased structural diversity within the library of compounds it tested during screening. As 
the demands of industry increased for a more diverse set of scaffolds for screening, natural 
products, while still useful, represented only a small portion of the diversity possible and began 
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taking a back-seat to large synthetic libraries. It was much easier to synthesize structural 
diversity in-house than to comb through the growing political tensions regarding intellectual 
property rights with local governments of the foreign countries where many natural products are 
collected.
17, 18
 Limited collection regions are also extended into the oceans where it can be 
difficult to collect or even explore for diversity beyond the upper ocean.
9
 Even if an agreement is 
reached, the biomass required to isolate practical amounts of a single usable compound can often 
times be enormous and taxing on the sustainability of the species being harvested for large scale 
medicinal purposes (ex. Taxol).
19
 Additionally, many companies terminated their natural product 
research programs due to limited financial returns on their investments and instead began 
searching for “blockbuster” drugs to recoup the investments required to push leads through 
development and into the clinic.
20
  
Many other inherent problems also arise during progression of natural products into clinical 
trials. Once isolated and identified as leads, some natural products are unable to be reisolated for 
further evaluation. Occasionally the organism producing the compound of interest may not 
continue producing it due to environmental stresses, location of collection, or disappearance of 
the species. Natural products are often limited by structural complexity and can be difficult to be 
reduced or expanded into useful pharmaceutical agents. While natural products can often display 
impressive selectivity and potency for a given target, they can also exhibit an unimpressive 
pharmacokinetic profile in the areas of bioavailability, solubility, metabolic stability, and 
toxicity.
19, 21
 When combined, all these factors determine whether or not a given compound can 
be used or developed into an agent with successful therapeutic utility. Previous examples have 
proven that semisynthetic modifications to complex natural products can improve their 
pharmacological properties.
21
 However, with the highly complex structures often including 
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multiple chiral centers and the highly functionalized scaffolds many natural products possess, it 
can be very difficult and time consuming to perform even the most basic of chemical 
transformations during the lead development phase.  
As previously mentioned, there are many challenges to natural product chemistry, however, 
it still remains an excellent source of both new structural diversity as well as leads for potential 
pharmaceutical agents.
18
 Recent trends show pharmaceutical companies terminating their natural 
product programs while the number of new drugs reaching market that are natural product 
related remains relatively constant.
15
 Despite the rise in combinatorial chemistry techniques, 
natural products as a whole still have a chance for a rebirth within large pharmaceutical 
companies as advances in scientific methodology catches up to the limitations of the natural 
product scaffolds.
14
 While more sources of natural products are being explored the vast majority 
remain undiscovered and available for future applications in medical settings.
9, 16, 17
 With the past 
success of natural products and their numerous unexplored sources, natural products surely have 
a place in the future of pharmaceutical research.  
Natural Products in Current Medicine 
Today as many as 80% of all antibacterial and anti-cancer agents are either natural products 
or derived from natural product sources.
15, 22
 These agents were mostly isolated from either plant 
sources or microbial life and have been key tools to improving the quality of life and increasing 
lifespan to anyone in need of treatment. While almost all areas of modern medicine have been 
influenced by natural products, the areas of antibacterial and anti-cancer agents have been 
influenced most due to their evolutionary role.
10
 Thanks to natural products, many different drug 
classes for the treatment of cancer and bacterial infections have emerged. Some of these drug 
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classes include penicillins, tetracyclines, alkylating agents, cephalosporins, aminoglycosides, 
topoisomerase inhibitors, microtubulin stabilizers, and glycopeptides (Figure 2).
9, 15, 23
 The study 
of these drugs has not only improved treatment options and broadened our understanding of 
various disease states, but they have also helped identify new drug targets and pathways for 
further investigation of enhanced therapeutics. The improvement of cancer therapeutics has 
resulted in an increase in the five-year survival rate by 20% between the years of 1975 and 2004.  
7 
 
 
Opioids 
One natural product that has drastically changed the pharmaceutical industry is the alkaloid 
morphine. This natural product was isolated from the latex of the opium poppy Papaver 
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somniferum L. (Papaveraceae) by Friedrich Serturner in 1805.
24, 25
 Opium in general has been 
used for centuries and can be traced back to the Sumerians who cultivated and harvested it in the 
lower Mesopotamia region.
26
 Extracts of the opium poppy were used to treat pain and induce 
sleep. However, once morphine was extracted and isolated from the crude extracts it was sold in 
pure form around 1827 by Merck. It wasn’t until nearly 100 years later that the structure of 
morphine was proposed by Sir Robert Robinson in 1923.
27, 28
 Even after a structure for morphine 
had been proposed its complexity was not confirmed by total synthesis for an additional 30 years 
in 1952 by Gates and Tschudi.
29
 Much of the subsequent research and thousands of morphine 
analogues that were synthesized in the following years helped to mold the field of receptor 
pharmacology as we know it today. Some currently used over-the-counter and prescribed drugs 
were directly influenced from the early and late work involving morphine. Several of these drugs 
include codeine, dextromethorphan, hydrocodone, nalbuphine, levorphanol, benzomorphans, 
fentanyl, and buprenorphine (Figure 3).  
9 
 
 
Drawbacks of Opioid Use 
Opioids have been the most therapeutically valuable compounds for the treatment of pain for 
the past 2000 years.
30
 These compounds can potentially act at three opioid receptor subtypes, the 
 opioid (MOP) receptor, the  opioid (DOP) receptor, or the  opioid (KOP) receptor. However, 
the use of these agents is not without their shortcomings. Use of narcotic analgesics gives rise to 
adverse side effects such as respiratory depression, constipation, tolerance, and physical 
10 
 
dependence, all of which are mediated by the MOP receptors.
30, 31
 Prolonged use of opioids will 
decrease their therapeutic potential resulting in larger doses to reach the same level of efficacy. 
Upon building tolerance the body can adapt to the drug and become physically dependent on it to 
avoid withdrawal symptoms. Overdosing to reach a desired effect will most commonly result in 
death via respiratory depression.
32
 However, in a controlled setting such as the clinic, 
constipation is a more common side effect to MOP receptor agonists.
32
 Common to other 
marketed drugs, less consequential side effects observed with the use of some opioids also 
include nausea, vomiting, pruritus, and drug-drug interactions.
30
 Regardless of which symptoms 
are being exhibited, these negative side effects impose limitations to the utility in their 
therapeutic use.  
Despite their drawbacks, opioid analgesics derived from morphine are still the most widely 
prescribed medication for pain.
30
 The chemical scaffold possessed by the natural product 
morphine has been extensively explored in efforts to tune out the associated negative side 
effects. Through these structure-activity relationships (SAR) a vast amount of knowledge has 
been gained into the understanding of the opioid receptor system.  
Opioid Receptors 
Although morphine was isolated in 1806, it was not until 1954 that Beckett and co-workers 
proposed the idea of opioid receptors and then not until 1973 when opioid receptors were 
identified in mammalian brain tissue by Pert and co-workers.
33, 34
 Later in 1976 Martin and co-
workers used morphine, N-allylnormetazocine, and ketocyclazocine to classify opioid receptors 
into three different subtypes (Figure 4).
35, 36
 Upon noticing these three structures resulted in 
11 
 
unique pharmacological effects, opioid receptors were classified into MOP, DOP, and KOP 
receptors.
35, 36
  
 
Each of the MOP, DOP, and KOP receptor subtypes belong to the G-protein coupled receptor 
(GPCR) superfamily and commonly associate with the Gi/o proteins.
30
 The coupling to the Gi/o 
proteins decreases both intracellular calcium and cAMP production, which results in an 
inhibition of adenylate cyclase and many other downstream signaling effects used in cell 
communication.
37, 38
 Despite their similarities, each opioid receptor differs in receptor 
distribution, density, and the endogenous ligand used to activate it.
39
  
Expanding Opioid Receptor Research 
While the vast majority of opioid research originally focused on morphine and the structure 
activity relationships of the morphine scaffold at MOP receptors, the therapeutic utility of these 
ligands are limited due to the negative side effects associated with them.
30
 Due to these negative 
characteristics, the need for the development of novel ligands free of harmful side effects still 
remains. Expanding research to explore the DOP and KOP receptors has shown promise in both 
pharmacological profile as well as a reduced side effect profile.
40, 41
 As nature has provided 
many bioactive molecular scaffolds such as morphine, the ideal ligand may remain to be 
discovered from a different structural class of molecules found in nature. In particular, scaffolds 
12 
 
that have shown promise for such activity are peptides, alkaloids (beyond the morphine 
scaffold), flavonoids, and terpenes. These scaffolds provide an excellent starting point for the 
investigation of the DOP and KOP receptors. Terpenes represent an enormous amount of 
diversity encompassing more than 55,000 unique molecules found in nature.
42, 43
 However, when 
compared to alkaloids such as morphine, terpenes remain an underexplored area in opioid 
research despite their almost ubiquitous presence in nature.  
Much of the diversity found between terpenes and alkaloids can be explained from their 
biosynthetic origins in nature. Alkaloids contain one or more nitrogen atoms, which usually 
imparts a varying degree of basicity. These nitrogen atoms originate from amino acids and often 
contain the carbon skeleton from the precursor amino acid that is being incorporated into the 
alkaloid structure. While over 27,000 different alkaloids are known, only a few amino acids are 
utilized in alkaloid biosynthesis, namely ornithine, tyrosine, tryptophan, lysine, histidine, 
nicotinic acid, and anthranilic acid. Terpenes however represent a larger set of known molecules 
and originate from only two building blocks, dimethylallyl pyrophosphate and 3-isopentenyl 
pyrophosphate, each of these being a biochemically activated isoprene unit. Connection of these 
activated isoprene units in a head-to-tail fashion force all terpenes to have carbon skeletons that 
can be represented by (C5)n with any further modifications happening in conjunction with 
another pathway such as the acetate or shikimate pathways. 
One terpene that has recently gained attention due to its interesting pharmacological profile is 
salvinorin A. The neoclerodane diterpene salvinorin A does not resemble traditional opioid 
ligands like the morphine scaffold, including the absence of a basic nitrogen, yet it possess both 
affinity and efficacy for opioid receptors.
44
 Several studies have shown that modification to the 
salvinorin A scaffold can modulate activity at the opioid receptors and even alter the selectivity 
13 
 
between individual subtypes of opioid receptors.
45-51
 Interestingly, the KOP receptor has shown 
therapeutic potential over the MOP receptor in the treatment of peripheral pain management, 
drug abuse, anxiety, and depression.
30, 52-55
 These results suggest salvinorin A may be an 
excellent starting point for the investigation into the KOP receptor as a drugable target with a 
reduced side effect profile. 
Salvinorin A Background 
The hallucinogenic sage plant Salvia divinorum Epling & Játiva from the mint family 
Lamiaceae has been used for centuries by the indigenous people of Oaxaca, Mexico.
56-58
 The 
locals of Oaxaca have used S. divinorum for ethnomedical purposes, as well as during traditional 
divination ceremonies. The hallucinogenic nature of S. divinorum is favored during divination 
ceremonies for its abilities to produce visions, while local shaman have used it as a treatment for 
headaches, rheumatism and the semimagical disease called panzón de barrego, which roughly 
translates to swollen belly.
59, 60
 Despite being widely used within the culture of the Mazatecs of 
Oaxaca for many years, S. divinorum did not emerge in industrialized nations until the late 
1930’s.
61
 Traditional modes of use include chewing the leaves or making an infusion and then 
ingesting.
56-58
 In western culture, the dried leaves of S. divinorum are typically smoked or less 
often volatilized.
62, 63
 Originally isolated by Ortega in 1982, the main active component of S. 
divinorum was found to be the neoclerodane diterpene salvinorin A (Figure 5).
44, 56, 59, 64
 Upon 
isolation and testing, salvinorin A was determined to be a potent hallucinogen that is a selective 
and highly efficacious -opioid receptor agonist.
44, 65, 66
 Furthermore it was shown that salvinorin 
A does not illicit its action through activation of the serotonin 5-HT2A receptor as do many of the 
known classical hallucinogens such as psilocybin, mescaline, dimethyltryptamine (DMT), 2,5-
dimethoxy-4-bromoamphetamine (DOB) and lysergic acid diethylamide (LSD) (Figure 5).
44, 67
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Interestingly enough, salvinorin A rivals the potency of classical hallucinogens such as LSD 
and DOB having an active dose in humans ranging from 6 to 21 g/kg.
68
 These findings are 
made even more intriguing to the science community based on the structure of salvinorin A, 
which bears little structural resemblance to any of the other known hallucinogens previously 
mentioned, in particular with respect to its lack of a basic nitrogen, which for years had been 
considered a necessity for binding and efficacy at opioid receptors.
69-72
  
Current Salvinorin A Use 
With the ease of obtaining S. divinorum or salvinorin A through local “head shops” and 
internet sales, salvia use has become popular within certain cultures around the globe. In the 
United States S. divinorum plants, leaf extracts, and dried leaves with enhanced salvinorin A 
concentrations are readily available for use as a recreational or legal alternative to other 
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hallucinogens.
62, 73
 The use of such products has been increasing since the mid-1990’s, and as of 
2006 in the United States at least 1.8 million people aged 12 or older have used S. divinorum or 
salvinorin A containing products, while in 2008 4.4% of college students had reported using 
salvia at least once.
57, 58, 73, 74
 Use, however, has recently seen a stabilization at non-trivial levels, 
with lifetime use among youth remaining roughly constant around 6% between the years (2009-
2011).
75
 As the popularity of legal hallucinogens such as salvinorin A increases amongst the 
general public of the United States, Europe, and the rest of the world, its own popularity brings 
with regulations on salvinorin A and S. divinorum as a controlled substance.
76
 Regulation of 
salvinorin A in Florida has changed the views of some users about its use in terms of safety, 
frequency of use, and the ease of obtaining the drug.
77
 The resulting ban on its possession or use 
in certain areas by law has left many in the scientific community curious to the mechanism of 
action and pharmacological profile of such an agent, which has sparked much investigation into 
the pharmacology of salvinorin A.  
Salvinorin A in vitro Pharmacology 
Salvinorin A was identified in 2002 by Roth and coworkers as the first non-nitrogenous, 
naturally occurring opioid receptor agonist.
44
 Furthermore, salvinorin A was identified as a 
potent and selective ligand which targeted the KOP receptor. This was determined through the 
NIMH Psychoactive Drug Screening Program by screening against 51 molecular targets which 
included ligand-gated ion channels, molecular transporters, and human GPCR’s. In this 
screening panel salvinorin A did not bind to MOP or DOP receptors; instead salvinorin A 
selectively inhibited bremazocine-labeled KOP receptors, effectively identifying an opioid 
receptor subtype specific ligand.
44
 Later in 2004 a detailed report of salvinorin A’s functional 
properties were evaluated by Chavkin and coworkers.
65
 Salvinorin A was compared to the 
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known KOP receptor agonist U69,593 and again found to be a potent agonist in all assays 
performed based on its ability to inhibit forskolin stimulated cAMP activity, potassium 
conductance, and intracellular calcium mobilization. Further KOP receptor subtype selectivity 
has been suggested by Ansonoff and coworkers by assessing salvinorin A’s ability to bind either 
KOP1 or KOP2 employing ligand binding as evidence.
78
 Ansonoff and coworkers showed that 
salvinorin A imparted selective affinity towards the KOP1 receptor over the KOP2 receptor (Ki = 
18.7 nM vs. Ki = 10,000 nM).
78
 These results are of course only suggestive, as KOP receptor 
subtypes have not been identified through gene coding but are only hypothesized through ligand 
binding.
79-81
  
Salvinorin A was shown to have similar affinity and potency as compared to U50,488 as well 
as being shown to promote KOP receptor internalization by Wang and coworkers.
66
 Salvinorin 
A, in CHO cells, had reported affinity and activity values of Ki = 7.9 nM and EC50 = 4.6 nM 
while U50,488 had reported values of Ki = 11.0 nM and EC50 = 2.2 nM. U50,488 and U69,593, 
both KOP receptor agonists, have previously been shown to down regulate and internalize KOP 
receptors.
82-84
 This internalization is often attributed to the development and mechanism of 
action of tolerance.
85-87
 After incubation of salvinorin A with cells expressing FLAG-hKOP 
receptors, a reduction of cell surface fluorescence was noted in a dose dependent manner. The 
reduction of cell surface fluorescence largely indicates the internalization of the FLAG-hKOP 
receptors. As compared to U50,488 salvinorin A was about half as effective at internalizing KOP 
receptors as U50,488 (15% vs 30 - 40% respectively).
66 
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Salvinorin A in Non-human Primates 
The pharmacokinetic profile of salvinorin A has been investigated in non-human primates 
and in rare instances during controlled human studies. In 2004 salvinorin A was administered to 
non-human primates by Butelman and coworkers and was shown to produce -opioid agonist-
like discriminative effects in rhesus monkeys.
88
 Using rhesus monkeys trained to discriminate for 
U69,593 against vehicle, salvinorin A was shown to fully substitute for U69,593 in a dose 
dependent manner. Upon pretreatment with the general opioid antagonist quadazocine, at the 
pharmacologically active dose of 0.32 mg/kg, the discriminative effects of salvinorin A and 
U69,593 were fully blocked in all test subjects. Pretreatment with the longer acting KOP 
selective antagonist 5’-Guanidinonaltrindole (GNTI) blocked the effects of salvinorin A in two 
of the three subjects. However the NMDA antagonist ketamine, known to produce 
psychotomimetic effects in humans, was not generalized by the U69,593 discriminante rhesus 
monkeys.  
Pharmacokinetic profiling of salvinorin A was described in non-human primates by Schmidt 
and coworkers in 2005.
89
 In this study a single bolus dose of salvinorin A (0.032 mg/kg) was 
administered intravenously to 2 male and 2 female rhesus monkeys. Across the four subjects the 
overall elimination t1/2 was 56.6 ± 24.8 min; however, gender differences were noticed for both 
the distribution and elimination of salvinorin A. In males, the distribution t1/2 was rapid, the 
elimination t1/2 was 37.9 ± 5.6 min, and the area under the curve (AUC) was 572 ± 133 ng 
min/ml. In females, the distribution t1/2 was slower than males at 0.95 ± 0.20 min, the elimination 
t1/2 was higher than males at 80.0 ± 13.1 min, and the AUC was larger than males at 1087 ± 46 
ng min/ml. These results are consistent with other observations involving KOP receptors and 
non-human primates.
90, 91
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Later, in 2007, Butelman and coworkers used gonadally intact male and female rhesus 
monkeys to investigate the effects of salvinorin A in a neuroendocrine biomarker assay of 
prolactin.
92
 Upon administration of salvinorin A and U69,593 (0.0032-0.056 mg/kg i.v.) a dose-
dependent and time-dependent increase in prolactin was observed. In male subjects, salvinorin A 
showed increased prolactin levels 5 minutes after injection. However, U69,593 had increased 
prolactin levels and a longer duration of action lasting out to 120 minute post administration as 
compared to salvinorin A which at 90 minutes was not significantly different than vehicle 
prolactin levels. Switching the route of salvinorin A administration to subcutaneous injection 
produced a slower onset and lower prolactin levels with peak effects not occurring until the 60 
minute time point. Additionally using nalmefene, which antagonizes MOP receptors at low 
concentrations and antagonizes both MOP and KOP receptors at high concentrations, Butelman 
was able to show that nalmefene (0.01 mg/kg, s.c.) did not antagonize the prolactin effects of 
salvinorin A, but at an elevated dose of 0.1 mg/kg the prolactin effects of salvinorin A were 
antagonized. Ketanserin, a 5-HT2 antagonist, when administered i.m. at an active dose of 0.1 
mg/kg, did not antagonize the neuroendocrine effects of salvinorin A. This further implicates that 
the effects of salvinorin A act through modulation of the KOP receptor. 
The pharmacokinetic parameters of salvinorin A were measured in female baboons by 
Hooker and coworkers in 2008.
93
 Using positron emission tomography (PET) with an 
11
C-acetyl 
derivative of salvinorin A, Hooker was able to show that 3.3% of the total salvinorin A 
administration reached a peak concentration in only 40 seconds with a half-life of 8 minutes. The 
highest concentrations within the brain were reached in the cerebellum with a notable amount 
being found in the visual cortex, which is hypothesized to account for, in part, the hallucinogenic 
effects observed when smoking salvinorin A. Administration of the opioid receptor antagonist 
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naloxone did not reduce or alter the distribution of salvinorin A administration. Peripheral organ 
kinetics suggested salvinorin A is metabolized through either the renal or biliary systems. Based 
on the maximum brain concentrations observed, it was presumed that less than 10 mg of 
salvinorin A within the brain is required to cause hallucinations. These findings are consistent 
with the observed and anecdotal effects described of humans when smoking salvinorin A.  
In 2009, Butelman and coworkers investigated the entry of salvinorin A into the central 
nervous system (CNS) and its unconditioned behavioral effects in non-human primates.
94
 
Sedation, postural relaxation, ptosis, and facial relaxation were all measured as a means to 
quantify the effects of centrally penetrating KOP receptor agonists. Upon administration of 
salvinorin A (0.032 and 0.1 mg/kg i.v.) dose dependent increases in sedation were observed in 
both chaired and home-cage subjects, as well as dose dependent increases in postural effects in 
home cage subjects out to 30 minutes. Salvinorin A was also shown to cause dose-dependent and 
time-dependent effects on facial relaxation and ptosis following intravenous administration. 
Compared to the known KOP receptor agonist U69,593, a shorter duration of action and more 
pronounced time-dependent behavioral effects were observed when administering salvinorin A. 
Upon pretreatment with the opioid antagonist nalmefene (0.1 mg/kg), the effects of salvinorin A 
were prevented and after administration of nalmefene 11 minutes post salvinorin A 
administration. Additionally, nalmefene rapidly reversed salvinorin A induced ptosis with facial 
relaxation being observed. These behavioral effects were further linked to KOP receptor 
modulation when pretreatment of CB1 receptor antagonist rimonabant and 5-HT2 antagonist 
ketanserin were both ineffective at preventing salvinorin A induced behavioral effects.
94
  
Continued research by Butelman and coworkers in 2010 investigated the discriminative 
effects of salvinorin A in non-human primates.
95
 Butelman and coworkers showed rhesus 
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monkeys trained to discriminate salvinorin A generalized the centrally acting KOP receptor 
agonists bremazocine, U69,593 and U50488. However, only one of the three subjects 
generalized the peripherally restricted KOP receptor agonist ICI204,448. These results link the 
discriminative effects of salvinorin A to centrally acting KOP receptor agonists. Other MOP and 
DOP receptor agonists, fentanyl and SNC80 respectively, did not exhibit generalization with 
salvinorin A. Additionally, the serotonergic 5-HT2 hallucinogen psilocybin and the NMDA 
antagonist ketamine were not generalized. Quadazocine (0.32 mg/kg) blocked the discriminative 
effects of salvinorin A, while the 5-HT2 antagonist ketanserin (0.1 mg/kg) did not. This further 
supports the discriminative cue produced by salvinorin A is mediated by activation of the KOP 
receptor and a distinct mechanism from other hallucinogens. 
Salvinorin A in Humans 
The effects of salvinorin A in humans are relatively unexplored based on volume of 
experiments being conducted in a controlled laboratory setting. Most of the original hypotheses 
to the pharmacokinetic parameters were anecdotal, being based upon first hand witnesses and 
user experiences with salvia or salvinorin A. Many user experiences can be seen over the internet 
on popular video sharing websites such as YouTube.com which Lange and coworkers have used 
in an attempt to quantify the observable effects of salvinorin A after watching several of these 
videos.
96
 Many of these videos show symptoms commonly associated with salvinorin A such as 
speech and coordination impairment, hallucinogenic experiences, and a dysphoric “loss of self” 
feeling. KOP receptors were first implicated to be associated with psychotomimesis by Pfeiffer 
and coworkers in 1986.
97
 Exactly how KOP receptors mediate their hallucinogenic effects 
remains unknown, however since the work of Pfeiffer, dysphoria has been the best surrogate 
marker of KOP receptor agonism.  
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The first reports of controlled studies involving salvinorin A in humans have only appeared 
recently in the past few years. In early 2011, two reports were published only four days apart 
from two separate groups involving administration of salvinorin A to humans. One group, led by 
Mendelson and coworkers, investigated the sublingual effects of salvinorin A, while the other 
group led by Johnson and coworkers investigated the smoked effects of salvinorin A.
68, 98
 Upon 
sublingual administration of salvinorin A in a DMSO/PEG-400 (25:75) solution Mendelson and 
coworkers did not observe any physiological or subjective effects from salvinorin A greater than 
placebo.
98
 Even doses up to 4 mg did not affect pulse, blood pressure, O2 saturation, or core 
temperature. Subjects were questioned after dosing using the Subjective Drug Effects 
Questionnaire (SDEQ), Altered States of Conciousness Questionnaire (APZ-OAV), and Positive 
and Negative Affect Schedule (PANAS) but lacked to produce results significantly different 
from placebo. Attempts were also made at quantification of salvinorin A in the blood and urine 
but in all accounts was found to be below their limit of quantification. While previous claims 
have been made to the sublingual effects of salvinorin A these results indicate the bioavailability 
of salvinorin A to be low at best.
58
 However, when Johnson and coworkers administered 
salvinorin A via inhalation, definite subjective effects were observed and recorded out to 20 
minutes after inhalation.
68
 In agreement with Mendelson’s work, Johnson and coworkers did not 
see a significant increase in blood pressure or heart rate. After administration of salvinorin A 
ranging from 0.375 g/kg to 21 g/kg dose-related increases were observed in drug strength on a 
mystical-type experience questionnaire (Mysticism Scale) and a subjective effects of 
serotonergic hallucinogens questionnaire (Hallucinogen Rating Scale). Salvinorin A exhibited a 
unique profile of subjective effects with similarities to classical hallucinogens, including 
mystical effects. Time dependent drug strength ratings were assessed every two minutes for one 
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hour with peak ratings at the two minute time point. Participant narratives indicated the user 
experienced intense and unusual experiences that were characterized by feelings of energy, 
changes in spatial orientation, pressure on body parts, and strange and sometimes recurring 
themes between individual dosing sessions such as revisiting childhood memories, contact with 
entities, and cartoon-like imagery. The participants were largely behaviorally inactive which is in 
contrast to the chaotic effects observed in the online videos by Lange and coworkers.
96
  
A larger population of participants was used by Addy in 2012 to assess the acute and post-
acute behavioral and psychological effects of salvinorin A in humans.
99
 Consistent with previous 
reports, vital signs were recorded before and after inhalation and were found to be unaffected by 
salvinorin A. Participants were dosed with either 1017 or 100 g of purified salvinorin A 
dissolved onto 25mg of dried leaf material two weeks apart in a counterbalanced order. The 
participants’ behavior during each session was recorded by the researcher followed by a 
subjective effects questionnaire (Hallucinogen Rating Scale) immediately following each 
session. While on active doses (1017 g) participants moved, laughed, and talked much more 
often than on inactive doses (100 g), this is contrary to the findings of Johnson and 
coworkers.
68
 Participants also rated the subjective effects on the hallucinogen rating scale 
significantly higher on active doses, indicating hallucinogenic experiences. These results indicate 
similarities and differences between salvinorin A and other more classical hallucinogens.  
Ranganathan and coworkers, in 2012, explored the neuroendrocrine effects, psychotomimetic 
effects, perceptual alterations, and quantitative electroencephalographic (EEG) effects in humans 
after inhalation of biologically active doses of salvinorin A.
100
 Over three days, 10 healthy 
individuals who had previously used salvinorin A were administered either 0 mg, 8 mg, or 12 mg 
of salvinorin A in a randomized order. On the visual analog scale (VAS) salvinorin A produced 
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less drowsiness when administered at both low and high doses, common to anecdotal reports of a 
heightened sense of awareness. However, the VAS feelings of “high”, “calm”, “sad”, “irritable”, 
or “anxious” were unaffected by salvinorin A administration. Salvinorin A administration 
resulted in transient psychotomimetic effects as measured by increases on the positive and 
negative syndrome scale (PANSS), as well as the psychotomimetic states inventory (PSI). 
Salvinorin A administration also produced transient increases in perceptual alterations for both 
intensity and somaesthesia as measured by the HRS. Elevated levels of plasma cortisol and 
prolactin were observed, making this the first study to demonstrate the endocrine effects of 
salvinorin A in humans. As prolactin is well known as a biomarker of KOP receptor agonism in 
non-human primates, this provides compelling evidence of the centrally mediated effects of 
salvinorin A.
92, 101, 102
 The elevation in cortisol levels are additionally consistent with the 
elevating effects of other KOP receptor specific agonists observed in animals and humans.
103, 104
 
These data and observations may suggest that salvinorin A lowers dopamine levels within the 
tuberoinfundibular pathway to elevate prolactin levels while stimulating the hypothalamic-
pituitary-axis to increase cortisol levels. 
Most recently, MacLean and coworkers again investigated the dissociative, hallucinogenic, 
and memory effects of salvinorin A in individuals with histories of hallucinogen use.
105
 
Consistent with previous findings, the dose-related effects peaked at 2 minutes and rapidly 
dissipated, not having any effect on heart rate or blood pressure. Doses of 0.375 g/kg to 21 
g/kg were administered to a total of 8 healthy participants previously experienced with 
hallucinogens. Two participants reached a voluntarily stopping point where they absolutely 
refused to receive a dose equal to or higher than the 19.5 g/kg (second highest dose) previously 
received. Additionally half of the participants provided a maximal drug rating of 10 (the 
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strongest effect imaginable for salvinorin A) at one or more time points, either verbally or due to 
a completely unresponsive nature when prompted. Participants stated that salvinorin A effects 
were unique and very intense as compared to other hallucinogens they had experienced. While 
the average ratings of similarity to other hallucinogens were relatively low on the quantitative 
pharmacological class questionnaire, the ratings of overall similarity to classical hallucinogens 
increased linearly as a dose function, indicating participants judged salvinorin A to be only 
somewhat similar to classic hallucinogens. All except one participant exhibited a dose-related 
impairment in word recall and recognition for an auditory memory task. Additionally, ratings on 
“liking” and “good” effects increased across doses while feelings of “disliking” and “bad” 
effects were not significantly affected by dose, indicating a possible abuse liability.  
Conclusions 
While natural products have been exploited for many years in the pursuit of remedies to treat 
medical ailments, there still remains a large area for investigation and improvement of their 
current uses. As natural products have been used in nearly all areas of modern medicine and are 
still being used as a large portion of the present treatments available and being developed, their 
utility is invaluable to medical practitioners. Specifically, the field of opioid pharmacology could 
greatly benefit from the investigation of novel scaffolds and receptor selective ligands. Many 
natural products have limitations to their use, while opioids have severely limiting drawback, yet 
the use of morphine and its derivatives remains the gold standard for treatment of pain today. 
Since the discovery of salvinorin A as a novel scaffold for opioid receptors, it has garnered much 
attention for its potential to modulate opioid receptors with a reduced side-effect profile. 
Therefore the continued investigation of salvinorin A and its place in opioid pharmacology 
remains to be fully investigated, including its isolation and pharmacokinetic profiling.   
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CHAPTER II 
 
Rationale and Specific Aims 
Salvinorin A is a structurally unique KOP receptor agonist that has shown potential for 
therapeutic use. While structural optimization is still needed to eliminate the drawbacks of its use 
in humans, salvinorin A provides an excellent scaffold with altered pharmacology for the 
investigation of opioid receptors. With opioid receptors linked to therapeutically relevant 
physiological functions such as pain, mood disorders, and gastrointestinal problems, the need for 
a novel treatment beyond morphine is a large void yet to be filled by researchers. It is known that 
salvinorin A imparts a hallucinogenic effect on its user, however it does not impart this effect 
through a typical 5-HT2A mechanism that most classical hallucinogens operate by. As much 
effort has gone into the modification of the salvinorin A scaffold in attempts to alter the 
pharmacology and reduce its side effect profile, there still remains much to explore with the 
absorption, distribution, metabolism, excretion, and toxicity (ADMET) associated with 
salvinorin A.  
Specific Aim #1: Attempt to isolate salvinorin A in a fast and selective manner 
As salvinorin A has shown potential to be a therapeutically useful agent, the isolation of high 
purity salvinorin A from its source would be a great aid to the investigation to the utility of 
salvinorin A. Generation of a reactive handle for a polymeric resin could lead to an efficient 
process for the selective removal of specific compounds from a complex mixture. This method 
could potentially reduce the need for large solvent volumes, the time required for isolation, and 
the labor required for a process. Previous work has shown solid phase chemistry to be successful 
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and amendable to natural products. To further explore the utility of solid phase extraction, a 
reactive solid phase handle was designed and shown to be chemically reactive towards the 
salvinorin A scaffold.  
 
Specific Aim #2: Investigate the pharmacokinetics of salvinorin A in non-human 
primates and humans 
Before salvinorin A can be fully developed into a useful agent with altered pharmacological 
properties, the pharmacokinetic profile of salvinorin A itself must first be understood. Without 
knowledge of the basic pharmacokinetic properties such as bioavailability, distribution, and 
metabolic stability, accurate predictions for the modification to the salvinorin A scaffold cannot 
be made to enhance a desired parameter. While much work has been done to investigate 
salvinorin A in lower order animals, little has been done with the investigation of salvinorin A in 
higher order animals such as non-human primates and humans. To expand the understanding of 
the pharmacokinetic parameters of salvinorin A, time course graphs were generated to relate in 
vivo concentrations of salvinorin A in non-human primate cerebrospinal fluid and in human 
plasma, using a reliable and reproducible LC-MS/MS quantification method. 
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CHAPTER III 
 
Solid Support Reagents in Natural Product Chemistry 
The use of immobilized reagents and scavengers provides an exciting and practical means for 
working with and efficient preparation of novel compounds from natural product extracts. 
Whether isolating or derivatizing a compound, solid supports within the field of natural products 
provide an excellent opportunity for the future exploration, design, and synthesis programs in 
chemistry. Natural products, whose novel structures and molecular complexity are unlikely to 
come from a combinatorial library, are more likely to arise from the development of an efficient 
method for isolating novel natural products. These newly identified compounds could then be 
used for testing within biological assays or against the biological macromolecules associated 
with many complex disease states. Much of the more current research has been focused on anti-
cancer agents, while the search for natural products possessing utility for the CNS or 
neurosciences has taken a back seat, being underdeveloped.
106
 While natural products could 
provide many novel scaffolds and selective agents to better characterize receptor types and or 
biological pathways associated with CNS disorders such as anxiety, chronic pain, depression, 
and schizophrenia, they may be under investigated for multiple reasons. Historically the isolation 
and purification of natural products has not been easily adapted to a high-throughput format 
since it most often requires large amounts of time and labor. Additionally, even after isolation 
and purification are complete there remains the issue of structure elucidation, which can often be 
assigned incorrectly.
107
 These troubles have de-emphasized the exploration for novel biological 
probes from natural sources. At present there remains a lack of a general and efficient method for 
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the rapid isolation of natural products, which is a vital problem because until fully explored, the 
vast amount of structural and chemical diversity in nature will not be available for use as 
biological probes for investigating complex disease states.  
The use of polymer-supported reagents is one approach for the development of a general and 
efficient method for the isolation of natural products. Polymer-supported reagents and 
scavengers are able to simplify both synthetic and isolation procedures, and as such they have 
been widely employed though organic chemistry for this purpose.
108
 When compared to 
traditional solution phase chemistry, solid supported reagents have a major advantage in the 
work-up and isolation steps being significantly simplified to a simple filtration.
109
 Additionally, 
almost all organic transformation performed in homogenous solution phase can also be 
performed with the appropriate polymer-supported reagent.
110
 The commercialization of nearly 
every type of functionally supported resin makes solid phase synthesis a very useful and versatile 
resource for organic chemists.
109
 The versatility of solid-supported reagents is exemplified in the 
reported polymer-supported synthesis of the natural products (±)-epibatidine, (±)-oxomaritidine, 
(±)-plicamine, and carpanone (Figure 6).
111-116
 The successful syntheses of these natural 
products highlight the value, versatility, and applications of using immobilized reagents in 
natural product chemistry.  
 
29 
 
There are many advantages provided when using solid supported reagents instead of 
conventional solution phase synthesis.
110
 Most notably, excess reagents can be used to force 
reactions to completion and the remaining excess simply washed away during filtration without 
causing messy or extensive workup procedures. Chemical reagents or their by-products that are 
normally toxic, noxious, or in general hazardous to work with can also be immobilized onto a 
solid support thereby reducing the risk of inhalation or direct physical contact. Solid support 
systems are also easily adapted to automated synthesis, such as the split and pool method. Many 
of the standard analytical methods such as nuclear magnetic resonance (NMR), liquid 
chromatography-mass spectrometry (LC-MS), thin layer chromatrography (TLC), and high 
performance liquid chromatography (HPLC) can be applied to solid-supported systems as well 
since the chemistry is carried out in solution. Additionally, reagents immobilized on solid 
support permits the simultaneous use of multiple reagents that would not be compatible if used 
together in standard homogeneous solution phase chemistry. For instance it has been shown that 
using acidic and basic solid support reagents in “tea bags” can be used together in a single 
reaction vessel to perform chemistry.
117
  
While immobilized reagents are an excellent tool for the rapid cleanup of reaction mixtures 
facilitated by sequestration of by-products, used reagents, and remaining excess reagents, the 
functionality of the solid support may be limiting its usefulness as a specific “trap” for a target 
compound. Using an appropriately functionalized solid support that could selectively capture a 
natural product based on its inherent functionality such that the contaminating impurities could 
be washed away would be a very powerful tool in natural products research. Additionally, 
employing a clean and effective method of releasing the polymer bound molecule thus releasing 
the desired product in a pure form would speed and simplify the often extensive chromatographic 
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procedures used to isolate single compounds from natural product extracts. This could be 
accomplished using any number of reversible physical or chemical methods. Both ionic and 
covalent bonding interactions have previously been exploited to successfully purify products 
from complex reaction mixtures.
118-123
 Many solid phase extraction (SPE) kits are commercially 
available for analytical sample preparation that utilize these basic principles to isolate a desired 
analyte under a wide variety of conditions. Following these principles, a solid supported reagent 
could be generated to select for a specific functionality contained by a molecule such that a 
single entity is selectively removed from a mixture. 
One process uses a reversible and selective interaction between a resin bound metal which is 
linked to an organic metal chelating tag which in turn is then linked to a specific natural 
product.
124
 This approach combines the principles of conventional homogenous phase chemistry 
with both tagged reagent and catch-and-release methodologies. In this case the link used as the 
tag can be tailored to a specific need and subsequently immobilized onto the resin bound metal 
rendering it reactive yet insoluble. After use, a simple filtration can then isolate the resin and any 
unbound impurities or reactants will be washed away. The desired product can then be cleaved 
from the resin and the tag recaptured onto the resin, regenerating it for additional use. Many 
metals bound to resin and organic metal chelating molecules can be used for this style of 
procedure.
125-128
 However, linking a organic metal chelating molecule to an unknown natural 
product is difficult. Instead, isolating a natural product based on its inherent functionality and 
chemical properties would generalize the procedure rather than attempting to link the compound 
to a suitable pendant group.  
Another functionality, that is more specific than acid/base properties, is the presence of a 
furan ring. Furan rings are known to undergo Diels-Alder reactions with acetylenedicarboxylic 
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acid derivatives.
129-131
 Additionally, it is known that by heating a Diels-Alder cycloadduct a retro 
Diels-Alder reaction will occur, which is driven by rearomatization. This inherent chemical 
property can then be used as a new catch-and-release method if bound to a solid support. This 
would allow for the capture and release of furan containing natural products via immobilization 
onto a solid support and then released after washing away the remaining unbound impurities. 
While Diels-Alder chemistry has previously been employed on solid support, this method has not 
been applied to natural product isolation.
132, 133
 Furthermore, this methodology has been 
amendable to solid support via use of a stabilized iminonitroso Diels-Alder reaction to derivatize 
complex diene containing natural products.
134-137
  
With the previously mentioned concepts in mind, efforts were then begun to develop a 
reactive resin, or resin appendage, that could react with salvinorin A. The selective reaction of a 
polymer with salvinorin A could potentially be used to molecularly sequester salvinorin A in an 
efficient manner. Taking known salvinorin A reactivity into account, the selective reaction with 
salvinorin A would need to be reversible, high yielding, and proceed under mild conditions to 
retain the salvinorin A scaffold intact. Investigations therefore proceeded into the reactivity and 
reversibility of Diels-Alder cycloadditions with the salvinorin A furan ring. 
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Results and Discussion 
Screening of a diverse set of dienophiles was conducted to understand the reactivity of the 
salvinorin A furan ring to participate in Diels-Alder cycloadditions. Initial reaction of dimethyl 
acetylenedicarboxylate with salvinorin A yielded a cycloaddition product that could be isolated 
and reheated in solution to perform the retro reaction and regenerate starting material (Scheme 
1). The cycloaddition of various electron deficient alkynes with the furan ring of salvinorin A 
and subsequent retro Diels-Alder to reform salvinorin A was not unexpected. There have been 
many reports of retro Diels-Alder reactions previously reported and used during chemical 
synthesis.
138-140
 These cycloaddition products were primarily being explored in efforts to 
modulate activity at the opioid receptors using salvinorin A as a chemical scaffold. 
 
This transformation and regeneration procedure is reaction specific between the dienes and 
dienophile partners. Therefore the utility of this reaction specificity was explored in an attempt to 
selectively isolate salvinorin A based on its inherent reactivity. Going beyond the use of alkynes 
to form cycloadducts, alkene reactivity with the furan ring of salvinorin A was also investigated. 
Attempts with maleic anhydride and maleimide to form cycloadducts with salvinorin A under 
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similar reaction conditions observed with dimethyl acetylenedicarboxylate yielded no reaction. 
In efforts to force the reaction towards the cycloaddition products, many variations in reaction 
conditions were performed that can affect Diels-Alder type reactions. After manipulation of time, 
temperature, solvent, addition of water, lewis acid catalysis, and microwave conditions, no new 
products were formed, as seen on TLC. However it was noticed that varying the concentration of 
staring materials in solution did begin to develop a new product as the starting materials became 
more concentrated in solution. Workable amounts of products were found after the concentration 
was near 100 mg of salvinorin A in 1 ml of chloroform. Using this information, the reactions 
were then performed as concentrated as possible by dissolving salvinorin A into liquid maleic 
anhydride. Carrying out these reactions neat resulted in near complete consumption of the 
salvinorin A starting material. While many of the alkene derivatives used were solids at room 
temperature, they needed to be heated to their melting points before the reaction could be run 
neat. Exploration of reaction scope with alkene dienophiles can be seen in (Scheme 2). 
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Upon isolation of the cycloaddition products derived from the reaction of salvinorin A with 
alkene dienophiles, the products were found to immediately degrade back to the respective 
starting materials. Degradation was noted via spotting an NMR sample onto a TLC plate and 
observing the reemergence of several different chemical entities. Clean NMR and HPLC spectra 
were unable to be obtained due to the regeneration of starting materials which introduced 
impurities into the samples. Even after HPLC purification, reinjection of the purified sample 
would begin to show additional peaks enter into the spectra, indicating that the cycloaddition 
products were not chemically stable rather than an initial purification problem. This dissociation 
of cycloadducts into respective starting materials may be due to the nature of the substituent and 
substitution pattern of the furan diene. Alkyl substituted furans have, when reacted with 
maleimide dienophiles, been shown to have an increased dynamic reversibility.
141
 Additionally 
3-substituted furans exhibit a decreased transition state free energy barrier making 
interconversion between cycloadduct and respective diene and dienophile easier.
141
  
While the information gained about the reactivity of the salvinorin A furan ring was valuable 
for development of a reactive resin, it was also disappointing to produce multiple salvinorin 
analogues that were unable to be evaluated at opioid receptors due to instability. In an effort to 
gain some information from these analogues the cycloadducts were attempted to be “trapped” via 
reduction of the oxanorbornene and oxanorbornadiene systems that results from the Diels-Alder 
reaction of furan with an alkene (Scheme 3). 
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 Although this did prove to be successful the resulting reduced systems proved to be very 
complex during structure elucidation. There are potentially four diastereomers that can be 
produced during the reduction, all of which would produce nearly identical spectroscopic data. 
These compounds were ultimately too hard to structurally verify even after attempts at inducing 
solid state NMR properties to gain residual dipolar coupling constants between unidentified 
protons.
142-144
 
Additional complications can arise from the cycloaddition with unsymmetrical alkynes. 
Facial attack of asymmetric alkyne dienophiles leads to additional isomers during the formation 
of the oxanorbornadiene system (Scheme 4).  
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Asymmetric alkyne adducts were still unable to be separated similar to previously mentioned 
alkene adducts. The regiochemistry remained scrambled and required additional synthetic 
procedures before isolation was successful (Scheme 5).  
Reaction of salvinorin A with ethyl 4,4,4-trifluoro-2-butynoate in toluene at 95°C afforded 
1a and 1b as a mixture of isomers in 48% yield. The isolated mixture was subsequently treated 
with Fe2(CO)9 in refluxing toluene to aromatize the oxanorbornadiene scaffold by 
deoxygenation. This process gave a mixture of isomers 2a and 2b which were separated by flash 
column chromatography using a gradient of 10 to 30% ethyl acetate in hexanes to afford 2a in 
3.6% yield and 2b in 62% yield.  
Determination of the regiochemistry relied heavily on NMR using the HMBC, HSQC, and 
COSY correlation of protons coupled to the splitting pattern observed in the fluorine coupled 
13
C 
NMR. Structures 1a – 2b were elucidated in a similar fashion to one another using the previously 
mentioned techniques. Specifically, in the case of structure 2a, the three aromatic protons at δ 
7.72, 7.69, and 7.50, which all correlate to aromatic carbons in the HSQC were identified first. 
Next the two protons at δ 7.72 and 7.50 were found to correlate to each other in the COSY 
spectrum, which would represent C-14 and C-15 (Scheme 5). Further analysis of the COSY 
spectrum showed that the proton signal at δ 7.69 did not correlate to any other protons, indicating 
that it was attached to the C-16 position. Examination of the HMBC spectrum then showed that 
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the proton signal at δ 7.72 was correlated to C-25, C-27, and C-13, while the proton signal at δ 
7.69 was correlated to C-28, C-26, and C-12. This would suggest that the COSY uncoupled 
proton signal from δ 7.69 is attached to C-16 and the COSY coupled proton signal from δ 7.72 is 
attached to C-15. 
 
 
Applying the information gained through probing the Diels-Alder reactivity of the salvinorin 
A furan ring towards the development of a reactive polymer, it was decided to proceed with an 
alkyne linked to a solid supported reagent. While the retro Diels-Alder reaction proceeded in 
lower yields for cycloadducts generated from alkynes than from alkenes (Scheme 6), an alkene 
dienophile could not be appended to the solid support due to the concentrations needed for the 
reaction to proceed.  
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A high reaction concentration could not be used since a natural product extract is often very 
thick and would mechanically prevent the reaction rather than if it was chemically reactive or 
not. Additionally, to aid in the chemical reaction of the Diels-Alder cycloaddition it would be 
beneficial to have a polymer precursor that could be reacted with salvinorin A and then 
polymerized. Efforts were then focus on ring opening metathesis polymerization (ROMP) for its 
ability to perform a late-stage polymerization. A late-stage polymerization would allow for harsh 
reaction conditions, if needed, while generating a tailor made reactive “arm” that could be used 
to sequester salvinorin A. 
One type of system that will undergo ROMP is the norbornene scaffold. The norbornene 
system had been previously shown to be useful in applications involving scavange-ROMP-filter 
and capture-ROMP-release techniques.
145, 146
 With the idea of capture-ROMP-release or ROMP-
catpture-release in mind for the molecular sequestration of salvinorin A from a plant extract via 
cycloaddition to the furan ring, this system was used as a building block for the generation of a 
reactive polymeric resin. Using the reactive properties of the salvinorin A scaffold towards 
alkyne dienophiles, a tether was modified for attachment to the norbornene system which 
contained an alkyne very similar to those known to react with salvinorin A (Scheme 7).
50
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Slow addition of -alanine to a solution of cis-5-norbornene-endo-2,3-dicarboxylic anhydride 
(3) in refluxing toluene yielded 4 in 65% yield, which could be used without purification. 
Compound 4 was then converted to the Weinreb amide via a 1,1’-carbonyldiimidazole mediated 
coupling to N,O-dimethylhydroxylamine to yield 5 in 99% yield, which could then be used 
without further purification. 5 was then converted to the resin precursor 6 by addition of a lithiate 
generated from ethyl propiolate and n-butyl lithium at -78°C. Resin precursor 6 was then used to 
test its reactivity towards Diels-Alder cycloaddition with the furan ring of salvinorin A as proof 
of concept that the polymerized resin would be adequate to link with salvinorin A. Compound 6 
was reacted with salvinorin A under standard cycloaddition conditions using toluene and heat to 
produce cycloadduct 7 in 50% yield. 
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Starting from 3 allowed for an easy point of divergence by simply adding in any amine 
necessary. The resulting products could then be easily purified by extraction, which would 
eliminate the need for large-scale chromatograph. -Alanine was selected since a two carbon 
linker between the functionality of the resin and polymeric backbone was believed to be enough 
space to allow for cycloaddition with salvinorin A as seen with the formation of 7. With proof of 
concept in hand, the reactive resin precursor was subjected to ROMP conditions in hopes of 
generating a polymeric resin. However, after several attempts at polymerization, a polymeric 
resin was unable to be generated. Only at the initial stage of resin synthesis with carbic 
anhydride 1 was polymerization successful (Scheme 8).  
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The failed attempts at ROMP were detrimental to project success. Without being able to start 
from the resin precursor there would be no way of knowing the loading capacity of the resin. 
While many solid phase reactions are monitored via disappearance of starting materials in infra 
red (IR) spectroscopy there would be no guarantee that disappearance of starting materials 
resulted in their addition to a polymerized resin. The subsequent chemical reactions would then 
be performed on faith hoping that the previous reaction had worked. Additionally any of the 
reactions during conversion of 4  to 6 that had not gone to completion would reduce yield, 
having been carried though the entire synthesis lowering the overall potential for loading 
capacity of salvinorin A onto the resin. Ideally the capture of salvinorin A onto solid support 
would occur with a resin of known loading capacity such that a percent recovery could be 
calculated when extracting salvinorin A from a plant extract. Minor attempts were conducted 
starting from a polymeric TentaGel resin of known loading capacity in which the polymeric 
backbone was insoluble, yet the chemically reactive “arms” were soluble in solution. However 
these arms, although soluble in solution, were unable to be seen on NMR without the use of a 
technique known as magic angle spinning. Therefore the use of a premade polymeric resin 
presented the same problems as the chemical synthesis of a custom resin.  
Conclusions and Future Directions 
The chemical reactivity of the salvinorin A furan ring has been probed in efforts to 
understand its amenability towards reversible Diels-Alder cycloadditions. Reaction of salvinorin 
A with electron deficient alkynes formed more stable adducts than when reacted with electron 
deficient alkenes. However with asymmetric cycloadducts structure elucidation becomes very 
time consuming and product isolation required additional synthetic procedures before isolation 
was able to be achieved. Being unstable, alkene cycloadducts that were formed immediately 
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degraded but were also 30% more likely to perform a retro Diels-Alder reaction under heated 
conditions. Taking these results into account a reactive handle was designed which contained an 
electron deficient alkyne similar to those known to form cycloadducts with the salvinorin A 
furan ring.  
The design of a reactive handle included the possibility that it could be polymerized into a 
functional resin. Upon generation of a functional resin precursor, it was reacted with salvinorin A 
and shown to form a stable cycloadduct. With the proof of concept in hand, the resin precursor 
was attempted to be polymerized. However, attempts at polymerization resulted in no reaction at 
any step along the synthetic pathway other than at the first step. 
While attempts at polymerization were unsuccessful, future work should focus on utilizing a 
premade polymer that can be functionalized directly in a single step to include an electron 
deficient alkyne for selective reaction with the salvinorin A furan ring. While this approach will 
encounter many of the same problems for product identification, a single step addition to a 
premade polymer would be amendable to using a large excess of reagent in order to drive the 
reaction to completion. However, a large excess approach in a multi-step synthesis is still subject 
to miscalculation of the resin loading capacity due to small amounts of unreacted material carried 
through the procedure. Using a premade polymer also has the advantage to be totally contained 
within a “teabag” for sequestering of the resin. This would be useful because the 
oxanorbornadiene systems that were being explored can potentially be soluble in some solvents. 
In this case, if the resin dissolved out of the “teabag” it would be lost to the plant extract, unable 
to be recovered in a selective fashion. 
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Experimentals 
All reagents purchased from chemical suppliers were used without further purification and 
reactions monitored using Thin-layer chromatography (TLC) on 0.25 mm Analtech GHLF silica 
gel plates using EtOAc/n-hexanes and visualized at 254 nm. Column chromatography was 
performed on silica gel (40 – 63 m particle size, 230-400 mesh) from Sorbent Technologies 
(Atlanta, GA). NMR spectra were recorded on either a Bruker DRX-400 with a H/C/P/F QNP 
gradient probe or a Bruker Avance AV-III 500 with a dual carbon/proton cryoprobe using  
values in ppm as standardized from tetramethylsilane (TMS) and J (Hz) assignments for 
1
H 
resonance coupling and 
13
C fluorine coupling. High resolution mass spectrometry data were 
collected on a LCT Premier (Waters Corp.) time-of-flight mass spectrometer. Analytical HPLC 
was performed on an Agilent 1100 Series Capillary HPLC system with diode array detection at 
254.8 nm on an Agilent Eclipse XDB-C18 column (4.6  150 mm, 5 mm) with isocratic elution 
in 60% CH3CN/40% H2O at a flow rate of 5.0 mL/min unless otherwise noted. 
General procedure for the cycloaddition of salvinorin A with alkynes: 
A solution of salvinorin A (0.462 mmol), appropriate alkyne (0.554 mmol), and toluene was 
allowed to stir at room temperature until homogeneous. The solution was then slowly heated to 
reflux over the course of an hour and allowed to stir overnight at reflux. The solvent was 
removed under reduced pressure and the resulting residue was subjected to flash column 
chromatography using a mixture of EtOAc/hexanes. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(5-(ethoxycarbonyl)-6-
(trifluoromethyl)-7-oxabicyclo[2.2.1]hepta-2,5-dien-2-yl)-6a,10b-dimethyl-4,10-
dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (1a) and 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(6-(ethoxycarbonyl)-5-
(trifluoromethyl)-7-oxabicyclo[2.2.1]hepta-2,5-dien-2-yl)-6a,10b-dimethyl-4,10-
dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (1b). 
Asymmetric cycloadducts 1a and 1b were synthesized as described by the general procedure 
using ethyl 4,4,4-trifluoro-2-butynoate to afford 402 mg of the combined mixture (48%) as a 
white powder, mp 119 – 121 °C; 
1
H NMR (500 MHz, CDCl3) δ 6.91 (dd, J = 1.9, 3.9, 1H), 5.76 
(s, 1H), 5.64 (dt, J = 1.8, 5.5, 1H), 5.61 (s, 1H), 5.39 (dd, J = 4.7, 11.0, 1H), 5.33 – 5.27 (m, 1H), 
5.15 (dd, J = 11.0, 19.9, 1H), 4.35 – 4.23 (m, 3H), 3.73 (s, 4H), 2.79 – 2.72 (m, 1H), 2.43 (td, J = 
5.4, 13.3, 1H), 2.31 (dd, J = 4.3, 10.6, 2H), 2.17 (d, J = 2.5, 5H), 2.13 (s, 1H), 2.09 (d, J = 8.7, 
1H), 2.03 (d, J = 12.3, 1H), 1.78 (d, J = 10.1, 1H), 1.61 (dd, J = 12.4, 21.2, 5H), 1.54 – 1.46 (m, 
2H), 1.41 (s, 4H), 1.37 – 1.29 (m, 4H), 1.11 (s, 4H); 
13
C NMR (126 MHz, CDCl3) δ 202.0, 
171.54, 171.53, 170.7, 170.4, 170.0, 169.9, 162.0, 161.5, 158.5, 157.9, 151.3 (q, 
3
JCF = 4.66), 
151.0 (q, 
2
JCF = 35.57), 150.8 (q, 
3
JCF = 4.87), 137.4, 135.8, 121.5 (q, 
1
JCF = 269.57), 121.4 (q, 
1
JCF = 269.63), 85.7 (d, 
3
JCF = 2.67), 84.5 (d, 
3
JCF = 2.52), 75.0, 74.9, 73.9, 72.7, 64.0, 64.0, 62.2, 
62.1, 53.50, 53.47, 52.0, 51.2, 51.0, 42.04, 41.99, 41.1, 40.4, 38.02, 37.96, 35.5, 35.3, 30.8, 30.7, 
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20.61, 20.58, 18.12, 18.08, 16.4, 15.3, 15.1, 13.9. HRESIMS (m/z): [M+Na] calculated for 
C29H33F3O10Na, 621.1924; found, 621.1986. HPLC 1a tR = 12.858 min; purity = 91.33%; 1b tR = 
11.759 min; purity = 8.67%. 
 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(3-(ethoxycarbonyl)-4-
(trifluoromethyl)-phenyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (2a) and (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-
acetoxy-2-(4-(ethoxycarbonyl)-3-(trifluoromethyl)-phenyl)-6a,10b-dimethyl-4,10-
dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (2b).  
A solution of 1a and 1b (200 mg, 0.33 mmol), Fe2(CO)9 (150 mg, 0.41 mmol), and toluene 
(15 mL) was allowed to stir at 60 °C for 20 minutes. Once the solution turned black, it was 
gradually heated to reflux and allowed to stir for 2 hours. The solution was filtered through a pad 
of celite and solvent was removed under reduced pressure. The residue was purified by column 
chromatography (gradient eluent: 10% ethyl acetate/90% n-hexanes - 30% ethyl acetate/70% n-
hexanes) to afford 121 mg of 2a (62%) and 8.2 mg of 2b (4.2%). 
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2a: white powder, mp 110-112 °C, 
1
H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.2, 1H), 7.69 
(s, 1H), 7.50 (d, J = 8.0, 1H), 5.62 (dd, J = 5.0, 12.0, 1H), 5.13 – 5.06 (m, 1H), 4.40 (q, J = 6.9, 
2H), 3.73 (s, 3H), 2.75 – 2.71 (m, 1H), 2.56 (dd, J = 5.1, 13.6, 1H), 2.30 (dd, J = 7.8, 13.5, 2H), 
2.24 – 2.18 (m, 1H), 2.16 (s, 3H), 2.13 (d, J = 8.3, 2H), 1.82 (d, J = 13.2, 1H), 1.66 (dd, J = 14.2, 
26.0, 2H), 1.52 (s, 3H), 1.49 – 1.43 (m, 1H), 1.39 (t, J = 7.2, 3H), 1.13 (s, 3H). 
13
C NMR (126 
MHz, CDCl3) δ 202.0, 171.5, 170.8, 169.9, 166.5, 144.4, 132.2 (q, 
3
JCF = 1.80), 128.4 (q, 
2
JCF = 
32.99), 127.8, 127.2 (q, 
3
JCF = 5.20), 127.0, 123.2 (q, 
1
JCF = 273.41), 77.6, 75.0, 63.8, 62.3, 53.6, 
52.0, 51.6, 45.1, 42.1, 38.1, 35.8, 30.7, 20.6, 18.1, 16.4, 15.2, 13.9. HRESIMS (m/z): [M+Na] 
calculated for C29H33F3O9, 605.1974; found 605.1959. HPLC tR = 16.767 min; purity = 99.93%. 
 
 
2b: white powder, mp 100-102 °C, 
1
H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.0, 1H), 7.66 
(s, 1H), 7.51 (d, J = 8.0, 1H), 5.62 (dd, J = 5.0, 12.0, 1H), 5.12 – 5.07 (m, 1H), 4.39 (q, J = 7.1, 
2H), 3.73 (s, 3H), 2.78 – 2.71 (m, 1H), 2.55 (dd, J = 5.1, 13.6, 1H), 2.30 (dd, J = 7.7, 13.5, 2H), 
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2.21 (d, J = 13.9, 1H), 2.17 (d, J = 5.8, 3H), 1.82 (d, J = 13.2, 1H), 1.69 (d, J = 14.4, 1H), 1.60 
(s, 3H), 1.52 (s, 3H), 1.46 (t, J = 12.8, 1H), 1.38 (t, J = 7.1, 3H), 1.14 (s, 3H). 
13
C NMR (126 
MHz, CDCl3) δ 202.0, 171.5, 170.8, 169.9, 166.4, 143.7, 131.3 (q, 
3
JCF = 1.83), 130.8, 129.4 (q, 
2
JCF = 32.66), 128.6, 123.7 (q, 
3
JCF = 5.38), 123.1 (q, 
1
JCF = 273.83), 77.7, 75.0, 63.8, 62.2, 53.6, 
52.1, 51.7, 45.1, 42.1, 38.1, 35.9, 30.7, 20.6, 18.1, 16.5, 15.2, 13.9 HRESIMS (m/z): [M+Na] 
calculated for C29H33F3O9, 605.1974; found 605.1979. HPLC tR = 16.705 min; purity = 89.59%. 
 
General procedure for the cycloaddition of salvinorin A with alkenes: 
Salvinorin A (0.231 mmol) and an excess of appropriate alkene were mixed heterogeneously 
in a 2 ml conical vial and slowly heated in an oil bath until the mixture became homogeneous, 
additional alkene was added as necessary until the salvinorin A was completely dissolved. The 
resulting mixture was stirred warm for 2 hours at which time the solution was diluted with THF 
(5 ml), 10% Pd/C (20 mg) added, and charged with H2. The resulting solution was allowed to stir 
overnight at room temperature. The solution was then filtered through a pad of celite and the 
resulting filtrate concentrated under reduced pressure to a solid residue. The residue was then 
purified by flash column chromatography using a mixture of EtOAc/hexanes. 
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Procedure for the synthesis of resin precursor: 
  (4) 
To a solution of cis-5-Norbornene-endo-2,3-dicarboxylic anhydride (7.39 g, 45 mmol) in 
refluxing toluene was added -alanine (8.02 g, 90 mmol) over the course of 15 minutes. The 
solution was then allowed to cool just below reflux and the reaction vessel fitted with a dean 
stark apparatus at which time the solution was brought back to reflux and allowed to stir 
overnight. To the solution was added 1 M HCl solution until the flask was free of solid 
particulates. The remaining toluene was then removed under reduced pressure and the resulting 
solution was extracted with CH2Cl2 and the combined organics dried over Na2SO4. Na2SO4 was 
removed via filtration and the filtrate concentrated under reduced pressure to yield 4 as a white 
solid (6.82 g, 64.4 %) which was used without further purification. Spectral data matches 
previously reported results.
147
 
 
  (5) 
To a stirring solution of (4) (6.64 g, 28.23 mmol) in THF (70 ml) was added 1,1’-
Carbonyldiimidazole (5.03 g, 31.05 mmol) and the resulting solution was allowed to stir at room 
temperature. After 1 hour, N,O-Dimethylhydroxylamine (3.17 g, 32.46 mmol) was added and 
allowed to stir overnight. Solvent was removed under reduced pressure and the resulting solid 
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was flushed with excess water and extracted with EtOAc. The combined organics were dried 
(Na2SO4) and the solvent was removed under reduced pressure to yield 5 as a white solid (7.767 
g, 98.8 %) which was used without further purification. 
1
H NMR (500 MHz, Chloroform-d) δ 
6.10 (s, 2H), 3.70 – 3.62 (m, 5H), 3.38 (d, J = 1.5 Hz, 2H), 3.26 (dd, J = 2.8, 1.5 Hz, 2H), 3.15 
(s, 3H), 2.60 (t, J = 6.9 Hz, 2H), 1.73 (dd, J = 8.8, 1.6 Hz, 1H), 1.53 (d, J = 8.8 Hz, 1H) 
13
C 
NMR (126 MHz, CDCl3) δ 177.49, 171.47, 171.45, 171.43, 134.41, 61.27, 52.17, 45.77, 44.91, 
34.08, 32.18, 32.15, 29.98 m.p. (88-89 °C) 
 
  (6) 
To an anhydrous solution of ethyl propiolate (0.546 g, 5.388 mmol) stirring in THF (30 ml) 
at -78 °C was added n-BuLi (3.367 ml, 5.388 mmol) dropwise and allowed to stir. After 15 
minutes an anhydrous solution of (5) (0.500 g, 1.796 mmol) in THF (6 ml) was added dropwise 
and the combined solutions allowed to stir at -78 °C for 1.5 hours. The reaction was then 
quenched with 15 ml of 1 M HCl, allowed to warm to room temperature, and extracted with 
EtOAc. The combined organics were dried over Na2SO4, filtered, and concentrated under 
reduced pressure to yield an orange oil. The oil was then subjected to flash column 
chromatography using a mixture of EtOAc/Hexanes (4:6) to yield 6 as a yellow oil (349 mg, 
61.6%). 
1
H NMR (500 MHz, Chloroform-d) δ 6.10 (d, J = 1.7 Hz, 2H), 4.31 (q, J = 7.1 Hz, 2H), 
3.69 (t, J = 7.1 Hz, 2H), 3.39 (s, 2H), 3.30 – 3.22 (m, 2H), 2.84 (t, J = 7.1 Hz, 2H), 1.74 (d, J = 
8.8 Hz, 1H), 1.54 (d, J = 8.8 Hz, 1H), 1.34 (t, J = 7.1 Hz, 3H) 
13
C NMR (126 MHz, CDCl3) δ 
182.47, 177.22, 152.00, 134.50, 79.68, 78.85, 63.12, 52.24, 45.73, 45.00, 42.55, 32.53, 13.92 
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Cycloaddition of Salvinorin A with Resin Precursor: 
  (7) 
A solution of salvinorin A (200 mg, 0.462 mmol), resin precursor (6) (200 mg, 0.634 mmol), 
and toluene was allowed to stir at room temperature until homogeneous. The solution was then 
slowly heated to reflux over the course of an hour and allowed to stir overnight at reflux. The 
solvent was removed under reduced pressure and the resulting residue was subjected to flash 
column chromatography using a mixture of EtOAc/hexanes (3:1) to yield 7 as a white solid (173 
mg, 50.1%). 
1
H NMR (500 MHz, Chloroform-d) δ 6.98 – 6.76 (m, 1H), 6.10 (ddt, J = 6.6, 5.0, 
2.1 Hz, 2H), 5.82 – 5.51 (m, 2H), 5.51 – 5.03 (m, 2H), 4.38 – 4.18 (m, 2H), 3.73 (d, J = 3.2 Hz, 
3H), 3.70 – 3.62 (m, 2H), 3.38 (dq, J = 3.8, 1.8 Hz, 2H), 3.25 (ddd, J = 9.9, 3.0, 1.6 Hz, 2H), 
3.20 – 3.00 (m, 2H), 2.79 (ddd, J = 56.8, 11.9, 4.7 Hz, 1H), 2.36 – 2.25 (m, 3H), 2.25 – 2.19 (m, 
1H), 2.19 – 2.14 (m, 4H), 1.81 – 1.70 (m, 2H), 1.66 – 1.51 (m, 5H), 1.42 – 1.24 (m, 8H), 1.10 (d, 
J = 3.3 Hz, 3H), 0.98 – 0.82 (m, 1H). 
13
C NMR (126 MHz, CDCl3) δ 202.15, 201.86, 196.91, 
177.37, 177.35, 177.30, 177.27, 171.62, 171.41, 170.96, 169.80, 161.95, 159.76, 157.76, 150.76, 
135.30, 134.36, 134.34, 86.13, 85.89, 85.35, 74.84, 74.81, 74.07, 63.55, 61.97, 61.75, 53.37, 
53.06, 52.03, 51.88, 51.83, 50.49, 45.68, 45.65, 45.62, 44.85, 44.83, 44.80, 41.90, 41.81, 41.24, 
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40.65, 37.83, 35.34, 35.31, 33.29, 30.67, 20.53, 20.48, 18.00, 16.24, 16.22, 15.12, 14.86, 14.02, 
13.97. 
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CHAPTER IV 
 
Quantification of Salvinorin A 
In order to proceed with the investigations of the biological, psychological, and 
pharmacokinetic effects salvinorin A imparts, a need for detection of salvinorin A in human and 
non-human primate biological fluids has arisen. Several methods have been developed for the 
detection of salvinorin A in human biological fluids.
148-153
 Other methods have focused on the 
quantification of salvinorin A in non-human fluids, herbal products related to S. divinorum, or 
directly from the extract or leaves of S. divinorum.
61, 65, 150, 153-158
  
One study quantified salvinorin A from a screen of commercially available leaves and leaf 
extracts of S. divinorum.
61
 In this study, Wolowich and coworkers found that samples from 
commercial sources contained significantly lower amounts of salvinorin A than advertised, 
ranging from 1 to 16% of the claimed amount. Additionally three of the five samples obtained 
contained contaminates of caffeine or vitamin E not normally found in S. divinorum or its 
extracts. HPLC-UV/Vis was used to analytically quantify salvinorin A at 208 nm while the 
caffeine and vitamin E were identified by TLC-GC/MS. This analysis method was first reported 
by Gruber and coworkers in 1999.
157
 This method however did not establish a limit of 
quantification, but was able to accurately measure amounts from 0.255 to 1.53 g, as seen from 
linear plots of the average peak height that achieved a correlation coefficient of 0.9997.  
Similar studies have been performed to investigate salvinorin A concentrations from leaves 
and extracts of S. divinorum even where salvinorin A and closely related neoclerodane diterpenes 
are produced in S. divinorum plants. Siebert in 2004 published a method for analyzing 
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chloroform extracts of fresh leaves by using TLC.
158
 It was concluded that salvinorin A and its 
closely related compounds are secreted as components of a complex resin that accumulates in the 
peltate glandular trichomes, specifically in the subcuticular space between the trichome head 
cells and the enclosing cuticle. Another study by Tsujikawa and coworkers used LC/MS in 
product ion scan mode to detect salvinorin A and salvinorin B and quantify them by HPLC-
UV/Vis from extract products circulating in Japan.
154
 After analyzing nine dried leaf and extract 
products salvinorin A and salvinorin B were found in be in the range of 3.2 to 5.0 / 0.10 to 0.17 
g/ml respectively for dried leaf products and 4.1 to 38.9 / 0.26 to 2.42 g/ml respectively in the 
extract products. Later in 2006 Medana and coworkers switched to a liquid chromatography 
method coupled to electrospray ionization multistage ion trap mass spectrometry (LC/ESI-IT-
MS) to identify salvinorins and divinatorins in S. divinorum leaves.
153
 The plant leaves were 
extracted with a mixture of acetonitrile/water (1:1) microfiltered and then subjected to LC/MS. 
The limit of detection (LOD) varied for each of the salvinorin and divinatorin compounds 
identified, however the reported LOD for salvinorin was found to be 3 ng/ml.  
Other types of analysis have also been performed for the quantification of salvinorin A 
including two-dimensional gas chromatography–time of flight mass spectrometry (GC x GC-
ToFMS) analysis of salvinorin A in plants, water, and urine.
150
 This study produced a LOD 
similar to LC-MS methods at 5 ng/ml with a linear range from 8 to 500 ng/ml. The benefit of 
using GC x GC was seen in the narrow time range of peak elutions, which allowed for effective 
separation of peaks of interest from matrix and chromatographic interferants. Additionally, this 
method only provides information on human samples that were spiked ex vivo with salvinorin A 
rather than collection of urine after administration of salvinorin A. Other studies have been 
conducted using the urine of participants who were believed to have consumed S. divinorum 
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after observation of eventually intoxicated patients.
148
 Using microextraction by packed sorbent 
(MEPS) and GC-MS/MS Morano and coworkers also achieved LOD and linear ranges 
comparable to previously reported results. However by using MEPS instead of the more common 
extraction technique of solid phase extraction (SPE), they were able to reuse a single packed 
syringe up to 80 times.  
There have been four attempts at the quantification of salvinorin A out of human blood or 
blood plasma. One study by McDonough and coworkers validated their method for blood by 
using certified drug-free urine instead of certified drug-free blood in hopes to prevent blood 
esterases converting salvinorin A into salvinorin B on the basis that salvinorin A has a short half 
life.
149
 The group used LC-MS as their analytical method and had similar LOD and linear ranges 
as previously reported results. They later claim to investigate a unique case of salvinorin A 
testing where only blood was available for analysis, but do not provide any of the results. 
Another method was developed for detection of salvinorin A in plasma, urine, saliva, and sweat 
using GC-MS after extraction from their respective matrices.
159
 In this study Pichini and 
coworkers administered, via smoking, 75 mg of dried S. divinorum leaves containing 0.58 mg of 
salvinorin A to two participants. Unfortunately, both individuals refused to have blood samples 
drawn due to a vivid hallucination stage after smoking the dried leaves. However, salvinorin A 
was detected in saliva and urine but not in sweat after administration, indicating the mode of 
excretion is either via metabolism into salvinorin B or direct elimination in saliva and urine. 
Most recently Margalho and coworkers validated a procedure for the detection and quantification 
of salvinorin A in pericaridial fluid, vitreous humor, whole blood and plasma using GC-MS.
160
 
They report linear ranges from 5.0 to 100 ng/mL with determination coefficients higher than 0.99 
in each matrix with a LOD and LLOQ value of 5.0 ng/mL. Beyond new matrices (pericardial 
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fluid, vitreous humor, and whole blood) for detection and quantification of salvinorin A, this 
method didn’t improve on the previously known LLOQ or techniques and instrumentation for 
analysis. Perhaps the most successful method was conducted by Schmidt and coworkers in 
2005.
151
 Blood and cerebrospinal fluid (CSF) samples were used from a male rhesus monkey 
never exposed to salvinorin A or S. divinorum. The only major drawback to this study is that 
samples were artificially spiked with salvinorin A after collection. In this fashion a metabolism 
study was done by incubating salvinorin A in blood and periodically sampling for concentrations 
of salvinorin A and salvinorin B. After 30 minutes the concentration of salvinorin B exceeded 
the concentration of salvinorin A, suggesting blood esterases rapidly perform this transformation. 
A linear range was reported between 2 and 100 ng/ml with a limit of quantification (LOQ) of 2 
ng/ml according to FDA guidelines. This method was then applied to the quantification of 
salvinorin A in the CSF of rhesus monkeys.
89
  
As these methods had used artificially spiked samples of human plasma and non-human 
primate CSF, efforts were then begun to develop a reliable and reproducible LC-MS/MS method 
for the quantification of salvinorin A from unspiked biological fluids. With a reliable method for 
quantification, investigations into the pharmacokinetic profile of salvinorin A in humans and 
non-human primates could then be explored. Beginning attempts for elucidation of the salvinorin 
A pharmacokinetic profile would be focused on its duration of action within a biological system 
by creation of time-course graphs to show the in vivo concentrations of salvinorin A after dosing. 
As salvinorin A is also CNS active, the anecdotal short duration of action would also be 
investigated by testing whether or not salvinorin A is a Pgp substrate, which could explain its 
rapid entry and exit from the CNS.  
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Results and Discussion 
The behavioral effects of salvinorin A in rhesus monkeys, the central nervous system (CNS) 
levels of salvinorin A and its sensitivity to modulation by the P-glycoprotein (Pgp) transporter in 
the blood brain barrier were investigated.
161
 Previous in vitro work with salvinorin A had 
suggested it may be a substrate of Pgp, being effectively effluxed from the CNS, thus giving rise 
to its short duration of action.
162
 To investigate whether salvinorin A was a Pgp substrate in an in 
vivo system, the competing Pgp substrate loperamide (0.032-0.32 mg/kg) and the selective Pgp 
inhibitor tariquidar (0.32-3.2 mg/kg) were administered independently to examine their effects 
on the unconditioned behavioral effects salvinorin A imparts. Control experiments with single 
doses of salvinorin A (0.0032 – 0.01 mg/kg) yielded non-zero scores for both ptosis and facial 
relaxation with a fast onset of action. In another control experiment, U69,593 known to be a very 
poor Pgp substrate and potent KOP receptor agonist was not affected upon pretreatment with 
loperamide or tariquidar. Upon pretreatment with either loperamide or tariquidar, a dose-
dependent enhancement of salvinorin A-induced ptosis, but not facial relaxation was observed 
(Figures 7 & 8).  
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Figure 7: 5-minute Pretreatment with loperamide (0.032 – 0.32 mg/kg) effects salvinorin A 
(0.01 mg/kg) induced ptosis, but not facial relaxation.
161
 
 
 
Figure 8: 30-minute Pretreatment with tariquidar (0.32 – 3.2 mg/kg) effects salvinorin A 
(0.01 mg/kg) induced ptosis, facial relaxation data not shown.
161
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At the largest doses of loperamide (0.32 mg/kg) and tariquidar (3.2 mg/kg) alone, there was 
no effect on ptosis or facial relaxation. However upon pretreatment with these agents for the 
proper time period they elicited a dose-dependent increase in salvinorin A induced ptosis but not 
facial relaxation. Cerebrospinal fluid (CSF) samples were also analyzed via LC/MS/MS and the 
amount of salvinorin A present was quantified in experiments with and without pretreatment 
with the Pgp inhibitor tariquidar. It was shown that upon pretreatment with tariquidar (3.2 mg/kg 
i.v.) enhanced peak levels of salvinorin A in CSF were observed, making this the first in vivo 
model to show the sensitivity of salvinorin A effects by modulation of Pgp (Figure 9). 
 
Figure 9: Pretreatment with tariquidar (3.2 mg/kg) increases peak salvinorin A (0.01 mg/kg) 
levels within the CSF 
Salvinorin A (0.01 mg/kg) exhibited a profile of consistent CSF levels after injection of 
salvinorin A in each subject, even immediately after intravenous injection, likely due to the time 
taken to administer salvinorin A intravenously. Peak salvinorin A levels were recorded at 1 and 2 
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minutes after administration and declined to <25% of peak values by 30 minutes post 
administration. Upon pretreatment with tariquidar a similar time course profile was observed but 
with higher recorded CSF levels. Peak levels of salvinorin A post tariquidar pretreatment were 
noted as being an approximately 90% increase over levels recorded for salvinorin A alone.  
While CSF samples are an acceptable biological fluid to use when working with rhesus 
monkeys, CSF is not an ideal source for quantification of salvinorin A in humans. The standard 
biological fluid to use when investigating pharmacokinetics in humans is blood plasma. The ease 
of acquiring, quantity, and versatile working conditions make blood plasma an ideal medium for 
the investigation of salvinorin A action in vivo with human participants.  
In a trial of seven human participants who smoked salvinorin A, plasma samples were 
collected at multiple times and various intervals (t = -2, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 60, 90 
min) in attempts to link the salvinorin A drug profile to the amount present in the blood plasma. 
Upon quantification and plotting salvinorin A can be found in blood plasma with a similar rapid 
increase in concentration and sharp decline in concentration as found in the rhesus monkey CSF. 
The peak salvinorin A concentrations found in blood plasma were also similar in profile (1 to 3 
minutes after smoking) which is consistent with the observed pharmacokinetic profile of 
salvinorin A (Figure 10).  
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Figure 10: Salvinorin A blood plasma concentrations for seven human participants over a 90 
minute time frame after smoking 18.0 g / kg (2 participants) or 21.0 g / kg (5 
participants) 
While a previous method has reported the detection of salvinorin A in CSF following i.v. 
administration, and in blood plasma samples spiked with salvinorin A, they employed lengthy 
SPE procedures and were limited by the use of MS1 scanning.
151
 With the preparation of CSF 
samples, lengthy SPE procedures were able to be removed which greatly reduced the sample 
preparation time to about one minute per sample. However with blood samples, SPE cartridges 
were repeatedly clogged such that it was impossible to pass solvent through. Early in the 
development it was apparent there was a broad variability in the propensity to clog an SPE 
column with plasma across participants, individual participant samples, and the commercially 
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processed pooled plasma used for standard curves. Therefore, the potential clogging of an SPE 
column was of real concern since a data point may be lost due to a limited supply of blood 
plasma being used up on a SPE column that clogs. Changing to a higher loading capacity SPE 
cartridge did slightly remedy the issue but did not completely stop the columns from becoming 
plugged. (Table 1). Due to the large injection volumes used on the instrumentation, it was not 
possible to reduce the amount of plasma loaded onto the SPE column and using a SPE column 
beyond 100 mg / mL would require a large elution volume making the reconstitution step less 
consistent and precise. With these restrictions in mind the Strata C18-E columns were used in all 
subsequent SPE work. 
Table 1: SPE columns used for salvinorin A extraction from human plasma 
SPE Column Loading Capacity SPE Attempts Attempts Plugged Plasma Volume 
Strata C8 100 mg mL
-1
 5 2 400 L 
Strata C18-E 100 mg mL
-1
 5 2 400 L 
Oasis HLB 30 mg mL
-1 
5 5 200 L 
Strata-X 30 mg mL
-1
 5 5 200 L 
Strata-X-C 30 mg mL
-1
 5 5 200 L 
Strata-X-CW 30 mg mL
-1
 5 5 200 L 
 
Even after pretreatment of plasma samples with cold ethanol or cold acetonitrile, the SPE 
columns were still clogged at approximately the same rate as previously noted. It was then 
assumed that while the SPE columns were still being overloaded that they might be mechanically 
blocked by particulates within the samples themselves. Upon centrifugation at 21,000 rpm for 4 
minutes the plasma was split into a pellet, clear plasma, and a fatty lipid-like layer. After loading 
the clear plasma, middle layer, onto an SPE cartridge it easily passed through and allowed for 
free flow of solvent through the column with minimal vacuum pressure. 
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Extra workload was placed on the HPLC guard column due to the removal of SPE workup 
from the CSF samples and residual impurities in the plasma samples. A slow clog in the HPLC 
guard column raised the pressure within the instrument over a period of injection cycles, which 
required changing the guard column after the pressure had increased to over 4600 psi, but never 
until all injections had been completed from a single participant series. Injections ranged from 70 
to 400, depending on sample quality, before the pressure dictated repacking the guard column.  
Once the sample preparation was reproducible for both CSF and plasma the appropriate 
internal standard was selected. Previously a +3 mass analogue had been used as an internal 
standard with an APCI source and SIM in MS1 successfully.
151
 However when applied to 
MS/MS the increased sensitivity reveals a slight impurity of salvinorin A within the +3 internal 
standard, observed as cross-talk between mrm channels with pure internal standard injections. 
Presumably the small impurity is derived from deuteron-proton exchange with the glassware 
during synthesis. Following the published procedure in three separate incidences by two separate 
chemists yielded 2-3% of (433u)-salvinorin A mixed into the (435u)-salvinorin A in each case. 
To avoid mathematical manipulation during data processing a unique analogue was used as 
internal standard while a feasible synthesis could be worked out for a (438u)-salvinorin A 
analogue (Figure 11). 
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Internal standard 8 was used for CSF samples because of its structural similarity, column 
retention, ionization similarity, and +28 mass units in relation to salvinorin A. In blank rhesus 
monkey CSF, collected in the absence of salvinorin A, no interference was detected on the 
chemical transitions monitored for the internal standard 8 and salvinorin A. Preparation of 
standard curve samples were done in artificial cerebrospinal fluid (ACSF) due to the limited 
supply of natural CSF. Upon alteration of previous synthetic methodology it was found that with 
extensive washing of glassware with D2O and performing the synthesis in a “perdeuterium” 
environment the cross-talk between the internal standard (9) and salvinorin A channels was 
eliminated by >99.99% as observed in the mass spectrometer. Since a separate internal standard 
had already been used in the processing of most CSF samples the isotopically pure (438u)-
salvinorin A was only used during the processing of human plasma samples. 
Percent recovery was determined using the ratio of integrated peak areas of salvinorin A 
undergoing SPE procedures versus salvinorin A injected from pure organic solvent. Precision 
was defined as the average standard deviation for each sample for three injections. Accuracy was 
defined as the deviation of the calculated concentration from the theoretical standard 
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concentration. Statistical data for CSF and plasma samples is summarized in Table 2 and Table 
3. The limit of quantification was defined as the point where signal to noise remained greater 
than 5:1 (Figure 12). Analytes remained stable for at least two weeks as that was the longest 
timeframe between injections of prepared samples. Matrix effects were not encountered in either 
CSF or plasma samples. 
Table 2: Salvinorin A statistical data from rhesus monkey CSF 
Parameter Value 
Linearity
1 
0.0125 - 50 ng mL
-1
 
(R
2
) ≥.998 
Limit of Quantification 0.0125 ng mL
-1 
(5.8 % , 10.96 %) 
Precision (Interday, Intraday)
2 
CV ( < 1.7 % , < 1.3 %) 
Accuracy (Interday, Intraday)
2 
(9.42 % , 4.94 %) 
1
 Nine-point calibration curve ran in triplicate 
2
 Calculated from 3 sets of 27 injections each 
 
Table 3: Salvinorin A statistical data from human plasma samples 
Parameter Value 
Linearity
1 
0.25 - 50 ng mL
-1
 
(R
2
)
2 
0.997 - .999 
Limit of Quantification 0.05 ng mL
-1 
(4.7 % , 7.47 %) 
Precision (Interday, Intraday)
3 
CV ( < 3.47 % , < 2.85 %) 
Accuracy (Interday, Intraday)
3 
(12.37 % , 7.08 %) 
Percent Recovery 93% – 114% 
1
 Eight-point calibration curve ran in triplicate 
2
 Range of correlation coefficients over seven trials 
3
 Calculated from 7 sets of 24 injections each 
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Figure 12: (Panel A): LC/MS/MS chromatogram with a signal to noise measurement for the 
internal standard at a concentration of 2.86 ng mL
-1
. (Panel B): LC/MS/MS 
chromatogram and signal to noise measurement for salvinorin A at a concentration 
of 0.0125 ng mL
-1
  
Conclusions and Future Directions 
The method developed allows for the quantification of salvinorin A at and below 
behaviorally active doses from both non-human primate CSF and human plasma. The plasma 
samples showed an order of magnitude increase in sensitivity from previously reported results, 
while the CSF samples showed two orders of magnitude increase in sensitivity while eliminating 
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the SPE procedures. Major increases in sensitivity were derived from the increased peak 
concentration that resulted from analyte focusing large injection volumes on a small bore 
column. Additionally MS/MS transitions reduced chemical noise in the spectral output. 
However, backpressure on the LC and guard column does need to be monitored as reduction in 
sample work-up (CSF samples) and large injection volumes onto the small bore column slowly 
obstructed the guard column and increased the backpressure. The backpressure was relieved as 
needed by repacking guard columns upon reaching the pressure maximum (4600 psi) depending 
on sample cleanliness. The synthesis and use of new internal standards prevented cross-talk 
between mrm channels while eliminating the need for mathematical manipulation of the data due 
to impurities generated from deuteron-proton exchange during chemical synthesis. The method 
developed was then successfully applied to processing of human plasma samples, as well as non-
human primate CSF samples.  
Time course graphs generated from the processing of CSF and plasma samples indicate a 
rapid absorption and distribution of salvinorin A into the body and rapid clearance. Consistent 
with previous results and anecdotal reports, salvinorin A was found to reach a peak concentration 
in non-human primate CSF at 1 and 2 minutes post administration and 1 to 3 minutes post 
inhalation in human plasma. Additionally, salvinorin A was found to be a Pgp substrate in non-
human primates as indicated by the increase in peak concentration after administration 
pretreatment with the Pgp inhibitor tariquidar.  
These studies focused on the in vivo concentrations of salvinorin A and the behavioral effects 
it imparts, future work should focus on other basic pharmacokinetic parameters such as the 
metabolic stability and excretion of salvinorin A. With knowledge about the concentration 
required to impart a biological effect and the short duration of action observed, to be a useful 
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agent other basic pharmacokinetic parameters need to be investigated. As a theory of 
metabolism, the deacetylation of salvinorin A by blood esterases renders it inactive. By 
identifying the metabolites of salvinorin A, the metabolic pathway could be interrupted, 
extending its biological duration of action. Modification of the salvinorin A scaffold to increase 
its water solubility and its bioavailability would provide a preferred method of administration 
beyond inhalation or injection. While much more information about salvinorin A scaffold is 
needed before it can be properly developed, future studies need to focus on obtaining the basic 
pharmacokinetic profile of salvinorin A before an accurate conclusion can be made about its 
usefulness for future pharmaceutical use. 
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Experimentals 
Experimental Subjects 
Experimental studies in non-human primates were approved by the Rockefeller University 
Animal Care and Use Committee.
161
 Experimental studies conducted in humans were approved 
by the Institutional Review Board at the Johns Hopkins University School of Medicine. Human 
participants had given their informed consent before participation in any experimental trials. 
 
Chemicals and Solutions 
Salvinorin A was extracted from the dried leaves of S. divinorum following previously 
described methods.
163, 164
 All solvents used were purchased from the Sigma-Aldrich chemical 
company and were of HPLC quality. Preparation of the internal standard, (9), was conducted 
starting from salvinorin A by following procedures developed by Lovell and coworkers.
165
 All 
stock solutions were prepared at a starting concentration of 1.0 mg mL
-1
 in acetonitrile and 
cooled to 2 °C in a refrigerator for storage. All stock solutions were made again from fresh 
materials after a two week period to prevent changes in concentration or degradation of the 
analyte. SPE column washing solution contained 90 % Millipore H2O and 10 % methanol (v/v). 
SPE column elution solution consisted of 75 % dichloromethane and 25 % acetonitrile (v/v). 
Reconstitution solution was made of 64 % Millipore H2O, 35 % acetonitrile, and 1 % formic acid 
(v/v/v). 
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Synthesis of Plasma Internal Standard 
  (Internal standard, 438-Salvinorin A) 
[22,22,22-
2
H],[22,23-
13
C]-(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(furan-3-yl)-
6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate 
A 10 mL round bottom flask was first rinsed with D2O and then washed with soap/D2O and 
rinsed again with D2O then placed in an oven for drying. Once dry the flask was capped inside 
the oven with a septum and injected with 5.0 ml of CDCl3, before cooling the hot glass, then 
flushed with argon. After letting the glassware cool, 4-(dimethylamino)pyridine (6 mg, 0.05 
mmol) and pure salvinorin B (50 mg, 0.128 mmol) were added to the flask, after which the 
reaction vessel was again flushed with argon. Once dissolved, acetic anhydride – 
13
C4, d6 99 % 
13
C, 97 % D (55 L, 0.64 mmol) was added to the solution and allowed to stir at room 
temperature. While monitoring the reaction by TLC it appeared that the reaction was complete 
after only 3 hours, however it was allowed to stir for 7 hours to assure complete conversion of 
salvinorin B to the deuterium labeled 438-salvinorin A. Deuterated methanol (2 mL) was then 
added to the stirring solution and concentrated under reduced pressure. To the residue was added 
CDCl3 (6 mL) and washed with DCl (35 wt. %) in D2O (4 x 4mL). The organic layer was then 
concentrated under reduced pressure to produce a white solid in 95.3% yield (52.8 mg, 0.122 
mmol), which did not need further purification. Upon HPLC analysis it was found to be at least 
97.44% pure with no traces of salvinorin B in the chromatogram, tr=5.739 min. After analysis by 
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LC/MS/MS the isotopic purity of 438-salvinorin A to 433-salvinorin A was determined to be 
>99.99%. 
1
H NMR (500 MHz, Chloroform-d) δ 7.41 (dt, J = 1.7, 0.9 Hz, 1H), 7.39 (t, J = 1.7 
Hz, 1H), 6.38 (dd, J = 1.9, 0.9 Hz, 1H), 5.53 (ddd, J = 11.8, 5.2, 0.9 Hz, 1H), 5.15 (ddd, J = 10.7, 
8.8, 0.9 Hz, 1H), 3.73 (s, 3H), 2.80 – 2.71 (m, 1H), 2.51 (dd, J = 13.4, 5.2 Hz, 1H), 2.34 – 2.27 
(m, 2H), 2.15 (q, J = 2.6, 1.9 Hz, 1H), 2.08 (dd, J = 11.7, 3.0 Hz, 1H), 1.83 – 1.76 (m, 1H), 1.68 
– 1.56 (m, 4H), 1.45 (s, 3H), 1.12 (s, 3H 
13
C NMR (126 MHz, CDCl3) δ 200.27, 169.79, 169.38, 
168.22, 141.96, 137.66, 123.43, 106.62, 73.27, 70.29, 62.30, 51.81, 50.24, 49.63, 41.61, 40.34, 
36.39, 33.69, 29.00, 18.84, 16.38, 14.66, 13.45 
 
Preparation of Plasma Blanks 
Calibration standards were prepared by serial diluting stock solutions of salvinorin A and 8, 
these dilutions were then added to pooled human plasma containing the anticoagulant acid-
citrate-dextrose. Specific preparation was done by adding 350 L of plasma to a 1.5 mL 
microcentrifuge tube, to which was then added 100 L from a 10 ng mL
-1
 solution of 8, and 100 
L from an individual dilution of 1 from the full serial dilution set. Each sample was vortexed 
for approximately 3 or 4 seconds before submitting to solid phase extraction. Final standards 
contained a volume of 350 L of reconstitution solution containing salvinorin A at 
concentrations of 0.050, 0.10, 0.25, 0.50, 1.0, 2.5, 5.0, 10, 25, 50 ng mL
-1
, with 9 at a 
concentration of 2.86 ng mL
-1
 for each sample. 
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Cerebrospinal Fluid Blanks 
Calibration standards were prepared by serial diluting stock solutions of salvinorin A and 8 
which was added to sufficient artificial cerebrospinal fluid (ACSF). ACSF contained 126 mM 
NaCl, 2.5 mM KCl, 20 mM HEPES, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.4 mM CaCl2, and 
1.2 mM MgCl solution at pH 7.4. Final standard samples were composed in 1.0 mL volumes of 
ACSF containing salvinorin A at 0.0125, 0.125, 0.25, 0.50, 1.0, 2.5, 5.0, 10, 25, 50 ng mL
-1
, 
internal standard (8) at 2.86 ng mL
-1
, 10 % (v/v) acetonitrile, and 1.0 % formic acid (v/v). 
 
Preparation of Human Plasma Samples 
Vaporized doses of salvinorin A, either 18.0 (2 participants) or 21 µg kg
-1
 (5 participants) 
were inhaled by seven human participants. 12 blood samples from each participant were 
collected up to 90 minutes post inhalation followed by cold centrifuged to obtain blood plasma. 
Plasma samples were thawed on ice from storage at -80 °C until free of any frozen particulates. 
Plasma samples were then made by adding 400 L of plasma to a 1.5 mL microcentrifuge tube 
and centrifuged at 21000 × g for 4 minutes. Upon centrifugation the plasma sample was split into 
three distinct layers, particulates on bottom, clear plasma in the middle, and a fatty layer on top, 
with the majority of the volume composing the middle layer. From these layers 350 L of the 
middle layer was cautiously pipetted out leaving behind the top and bottom layers. This 350 L 
was then transferred to a new 1.5 mL microcentrifuge tube to which was added 100 L of a 10 
ng mL
-1
 solution of 9 in reconstitution solution. The resulting solution was then mixed by 
vortexing for approximately 3 or 4 seconds and subjected to solid phase extraction.  
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Preparation of Rhesus Monkey CSF Samples 
CSF samples containing salvinorin A were stored at – 80 °C until processing when samples 
were thawed on ice until they were free flowing and free of any ice crystals. Upon thawing 300 
L of CSF sample was transferred via pipette to a high recovery sample vial and diluted to a 
total volume of 350 L. Final solutions contained 10 % acetonitrile, 1.0 % formic acid, and 1.0 
ng of internal standard (8). Samples were then analyzed using multiple reaction monitoring 
(mrm) on a LC-MS/MS system. 
 
Soild Phase Extraction 
Strata C18-E 55 micron, 70   SPE cartridges (Phenomenex, Torrance, CA) were used for 
preparation of authentic human samples as well as standard curve samples. A Phenomenex 12-
port SPE vacuum manifold was used at vacuum pressure between 1 and 10 inches of Hg, 
depending on the viscosity of plasma, to maintain a flow rate of approximately 1 mL min
-1
. SPE 
columns were conditioned by washing sequentially with 3 mL of methanol and 3 mL of 
Millipore H2O. The columns were then loaded with plasma samples and rinsed with 3 mL of 
washing solution before removing solvent under gentle vacuum for approximately 5 minutes. 
Salvinorin A was then extracted from the columns using 2 mL of eluting solution, collected in 2 
dram vials, and solvent evaporated to dryness under a gentle stream of nitrogen gas at room 
temperature. Vials containing the dried extracts were then reconstituted into 350 L of mobile 
phase and transferred to a total recovery autosample vial.  
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Instrumentation 
Samples were injected and chromatographed using a Waters Acquity UPLC (Waters corp 
Milford, MA) which eluted into a Micromass Quattro Ultima (Micromass LTD Manchester, UK) 
triple quadrupole mass spectrometer operating with a positive electrospray source. Salvinorin A 
was separated from internal standard and any impurities using a Micro-Tech Scientific 1 mm I  
  5 cm  orbax C18 300   3.5 micron column preceded by a 2.0 cm × 1 mm ID guard column. 
Table 4 outlines the HPLC solvent gradient used for elution of analyte and internal standard. 
Data was collected and processed using MassLynx version 4.1 (Waters corp.), and all 
instrumental parameters used are summarized in Table 5. Repacking of guard columns was done 
manually 1 mm “kits” (upchurch / idex P/N C-128). 
 
Table 4: Solvent gradient program used for elution during LC-MS/MS analysis
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Time (min) Flow Rate % Solvent A† % Solvent B‡ 
Initial 0.135 99.0 1.0 
1.0 0.135 99.0 1.0 
2.0 0.135 71.0 29.0 
10.0 0.135 67.0 33.0 
10.1 0.145 5.0 95.0 
11.0 0.145 5.0 95.0 
12.0 0.130 99.0 1.0 
† Solvent A consisted of 99.0 % H2O and 1.0 % acetonitrile 
‡ Solvent B consisted of 99.92 % acetonitrile and 0.08 % formic acid 
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Table 5: Set parameters of instrumentation 
Parameter Set Value 
Ionization Mode ES+ 
Injection Volume 50.00 L 
Capillary 2.81 kV 
Source Temperature 100 °C 
Desolvation Temperature 250 °C 
Q1 & Q3 Resolution 0.8 amu, wh 
Collision Cell Pressure 1.55e
-3
 mbar 
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CHAPTER V 
 
Conclusions 
This work sought to isolate salvinorin A in a fast and selective manner, as well as investigate 
the pharmacokinetics and behavioral effects of salvinorin A in non-human primates and humans. 
These goals would allow for the investigation of salvinorin A and its utility to be a useful 
pharmacological agent. The selective and efficient removal of salvinorin A from a complex 
reaction mixture could also potentially be amended to other natural products or unknown 
reaction mixtures in search of a specific functional group. The pure salvinorin A could then be 
used to begin development of a pharmacokinetic profile in higher order species. 
In order to understand the retro Diels-Alder reaction of cycloadducts formed with the 
salvinorin A furan ring, several dienophiles were used to probe its chemical reactivity. It was 
found that the cycloadducts formed from reaction with electron deficient alkenes were unstable 
and performed a retro Diels-Alder reaction in a 35% yield. With electron deficient alkynes, 
cycloadducts were found to be stable for isolation, but only underwent a retro reaction in 5% 
yield. However asymmetrical alkynes complicate the reactivity by forming multiple inseparable 
isomers. While multiple isomers do not necessarily affect a retro reaction from occurring, they 
do complicate structure elucidation for applications such as SAR studies at opioid receptors. 
From these results, a handle for a functional resin was designed similar to alkynes known to react 
with salvinorin A.  
Using a oxanorbornadiene scaffold for the potential of polymerization, a reactive resin 
precursor was synthesized in a fast and efficient manner. This reactive resin precursor was 
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shown to form a stable cycloadduct with salvinorin A, but was not able to be polymerized once 
attached. Furthermore the oxanorbornadiene scaffold was unable to be polymerized at any stage 
of the synthetic procedure other than in the first step where it was unmodified. With these results, 
there appears to be far more disadvantages and obstacles than benefits for this method of 
extracting salvinorin A. In theory, the selective removal of a specific compound based on its 
inherent reactivity would seem like a novel technique for natural product exploration. However, 
with salvinorin A specifically the retro reaction proceeded in such low yields it would require an 
extremely large amount of both polymerized resin and solvent. This inevitably is characteristic of 
the traits we are trying to avoid and is counterproductive to the project. Instead future work 
should remained focused on the reactivity of the salvinorin A furan ring and its SAR for the 
opioid receptors. By manipulating the chemical properties of salvinorin A, investigations into 
developing improved pharmacokinetic and pharmacodynamic properties could be explored. 
Current isolation and purification techniques for salvinorin A are well investigated and already 
work on large scale, therefore focusing efforts instead to improving the water solubility and 
metabolic stability of salvinorin A would likely fill a much larger gap in the literature.  
The method for quantification of salvinorin A allows for behaviorally active doses to be 
detected in cerebrospinal fluid after i.v. injection in non-human primates and from plasma after 
inhalation in humans. Compared to previous methods, plasma samples showed an order of 
magnitude increase in sensitivity, while CSF samples showed two orders of magnitude increase 
in sensitivity while bypassing SPE sample preparation procedures. The major increases in 
sensitivity were derived from larger injection volumes with analyte focusing on a small inner 
diameter column thus increasing peak concentration. Additionally MS/MS transitions reduced 
chemical noise as expected. However, reducing sample preparation and large injection volumes 
77 
 
onto a small bore column slowly obstructed the guard column and increased back pressure due to 
slow clogging during repeated sample injections. Therefore these techniques do require the 
monitoring of back pressure on the LC and guard column which can be remedied by repacking 
the guard column as needed depending on sample cleanliness. New internal standards were 
synthesized and used to prevent cross-talk between mrm channels which eliminated the need for 
mathematical manipulation during data processing from impurities in internal standard.  
Time course graphs for the salvinorin A concentration in non-human primate CSF and in 
human plasma were produced. Peak concentrations were found at 1 and 2 minutes post injection 
in CSF and 1 to 3 minutes post inhalation in human plasma, with salvinorin A concentrations 
quickly declined over the next 15 to 30 minutes. The rapid absorbance and clearance were 
consistent with previously reported observations and anecdotal reports. One possible explanation 
for the fast off-set of salvinorin A is that it is a Pgp substrate as it was also shown that 
pretreatment with the Pgp inhibitor tariquidar increased peak salvinorin A concentrations within 
non-human primate CSF by around 90%.  
This work has completed the development of a method for the rapid quantification of 
salvinorin A from non-human primate CSF and from human plasma. This method then allowed 
for the generation of time-course graphs measuring the in vivo concentrations of salvinorin A 
during the short time it is biologically active after administration. These results, for the first time, 
where then quantitatively coupled to behavioral effects that salvinorin A imparts. Future work 
should focus on identification of other basic pharmacokinetic parameters such as the metabolic 
stability and excretion pathway of salvinorin A. Identification of the salvinorin A metabolites 
could lead to novel biomarkers for the future studies involving salvinorin A quantification in vivo 
and their correlation to behavioral effects.   
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